var title_f10_50_11040="Uric acid crystals in the urine";
var content_f10_50_11040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uric acid crystals in the urine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment loaded with uric acid crystals. These crystals are pleomorphic, most often appearing as rhombic plates or rosettes. They are yellow or reddish-brown and form only in an acid urine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11040=[""].join("\n");
var outline_f10_50_11040=null;
var title_f10_50_11041="Carbenoxolone: International drug information";
var content_f10_50_11041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbenoxolone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bioplex (GB);",
"     </li>",
"     <li>",
"      Bioral (AU, GB);",
"     </li>",
"     <li>",
"      Carbosan (IE);",
"     </li>",
"     <li>",
"      Herpesan (HK, MY, SG);",
"     </li>",
"     <li>",
"      Rowadermat (AT);",
"     </li>",
"     <li>",
"      Sanodin (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Carbenoxolone Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of esophageal inflammation and ulceration",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: One chewable tablet 3 times/day after meals and 2 tablets at bedtime for 6-12 weeks",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, chewable: 20 mg [contains alginic acid 600 mg, aluminum hydroxide 240 mg, magnesium trisilicate 60 mg, and sodium bicarbonate 210 mg]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10349 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11041=[""].join("\n");
var outline_f10_50_11041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303853\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978094\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978096\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978099\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978095\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821225\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978098\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10349\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10349|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_50_11042="Complete nail plate avulsion";
var content_f10_50_11042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Complete nail plate avulsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11042=[""].join("\n");
var outline_f10_50_11042=null;
var title_f10_50_11043="Patient information: Should I have a screening test for Down syndrome during pregnancy? (The Basics)";
var content_f10_50_11043=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15528\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21365\">",
"         Problems caused by Down syndrome",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/56/34690\">",
"          Child with Down syndrome",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/57/42897\">",
"         Patient information: Amniocentesis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/46/39663\">",
"         Patient information: Chorionic villus sampling (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/28/34242\">",
"         Patient information: Down syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/29/37331\">",
"         Patient information: Prenatal care (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/28/14785\">",
"         Patient information: Amniocentesis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/7/2161\">",
"         Patient information: Chorionic villus sampling (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/45/29394\">",
"         Patient information: Down syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/50/2851\">",
"         Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Should I have a screening test for Down syndrome during pregnancy? (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/should-i-have-a-screening-test-for-down-syndrome-during-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1665610398\">",
"      <span class=\"h1\">",
"       What is Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Down syndrome is a life-long condition that a person is born with. It can cause learning problems and medical problems affecting the heart, blood, stomach, and other organs (",
"      <a class=\"graphic graphic_figure graphicRef79537 \" href=\"UTD.htm?20/55/21365\">",
"       figure 1",
"      </a>",
"      ). The learning and medical problems in people with Down syndrome can be mild or severe.",
"     </p>",
"     <p>",
"      People with Down syndrome have a problem with their chromosomes. Chromosomes are large structures found in cells that house thousands of genes. People with Down syndrome have an extra chromosome. This causes their problems and makes them look a little different than people without Down syndrome (",
"      <a class=\"graphic graphic_picture graphicRef67446 \" href=\"UTD.htm?33/56/34690\">",
"       picture 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      About 1 in 700 babies is born with Down syndrome. A woman of any age can have a baby with Down syndrome. But a woman is more likely to have a baby with Down syndrome the older she gets. She&rsquo;s also more likely to have a baby with Down syndrome if she has a close family member with the condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610405\">",
"      <span class=\"h1\">",
"       What is a screening test for Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A screening test for Down syndrome is a test that can tell you if it is likely that your baby has Down syndrome. Screening tests do",
"      <strong>",
"       not",
"      </strong>",
"      tell you for sure if your baby has Down syndrome. Having a screening test does not increase a woman&rsquo;s chance of having a miscarriage. A miscarriage is when a pregnancy ends on its own.",
"     </p>",
"     <p>",
"      If a screening test shows that there is a high chance that a baby has Down syndrome, a woman can have another test to find out for sure.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610412\">",
"      <span class=\"h1\">",
"       Which tests can tell for sure if my baby has Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The tests that can do this are called &ldquo;diagnostic tests.&rdquo; Two types of diagnostic tests are available:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chorionic villus sampling, also called &ldquo;CVS&rdquo; &ndash; During CVS, a doctor puts a needle into the mother&rsquo;s uterus and removes a tiny piece of the placenta. The placenta is the organ that brings the baby nutrients and oxygen and carries away waste. CVS is usually done at 11 to 12 weeks of pregnancy, but it can be done as late as 14 weeks.",
"       </li>",
"       <li>",
"        Amniocentesis &ndash; During amniocentesis, a doctor puts a needle into the mother&rsquo;s uterus and removes some of the fluid that is around the baby. This test is usually done between 15 and 20 weeks of pregnancy, but it can be done later.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is important for women to know that diagnostic tests can have side effects. Women who have diagnostic tests have a small chance of having a miscarriage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610419\">",
"      <span class=\"h1\">",
"       Do all women have a screening test for Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But all women get to choose if they want to have a screening test. Some women choose to have a screening test, and others choose not to. You can decide if a screening test is right for you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610426\">",
"      <span class=\"h1\">",
"       Are different screening tests available?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Different screening tests are available depending on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How far along a woman is in her pregnancy &ndash; Different tests are done at different times during pregnancy.",
"       </li>",
"       <li>",
"        Where a woman lives &ndash; Different tests are available in different areas.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Screening tests can involve:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests &ndash; Blood is taken from the mother.",
"       </li>",
"       <li>",
"        Ultrasound &ndash; This is an imaging test that creates pictures of the baby.",
"       </li>",
"       <li>",
"        Both blood tests and ultrasound",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610433\">",
"      <span class=\"h1\">",
"       Why might a woman choose to have a screening test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A woman might have a screening test if:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        She wants to know as much as she can about her baby&rsquo;s health.",
"       </li>",
"       <li>",
"        She is worried about her baby. She feels that she will worry less if there is a low chance that her baby has Down syndrome.",
"       </li>",
"       <li>",
"        She wants to know if her baby has Down syndrome so that she can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Learn about Down syndrome before the baby is born",
"       </li>",
"       <li>",
"        Give birth in a hospital that has experience taking care of babies with Down syndrome",
"       </li>",
"       <li>",
"        Choose whether or not to end her pregnancy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610440\">",
"      <span class=\"h1\">",
"       Why might a woman choose not to have a screening test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A woman might skip the test because:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        She feels that &ldquo;whatever will be, will be,&rdquo; and knows that she would never end a pregnancy. She will wait until her baby is born to see if it has Down syndrome.",
"       </li>",
"       <li>",
"        She knows that she would not have a diagnostic test even if her screening test showed that there was a high chance her baby had Down syndrome.",
"       </li>",
"       <li>",
"        She wants to know for sure if her baby has Down syndrome, so she will have a diagnostic test instead of a screening test.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610447\">",
"      <span class=\"h1\">",
"       What if my screening test shows that there is a high chance my baby has Down syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your screening test shows that there is a high chance your baby has Down syndrome, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a diagnostic test to know for sure if your baby has Down syndrome",
"       </li>",
"       <li>",
"        Not have any more tests done during pregnancy. You can wait until birth to have a test done to see if your baby has Down syndrome.",
"       </li>",
"       <li>",
"        Talk to an expert called a &ldquo;genetic counselor&rdquo; to help you make a choice",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610454\">",
"      <span class=\"h1\">",
"       How do I know which choice is right for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It can be tough to know which choice is right for you. To help you choose, talk with your doctor or nurse about the benefits and downsides of the different tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1665610461\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/28/34242?source=see_link\">",
"       Patient information: Down syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=see_link\">",
"       Patient information: Amniocentesis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=see_link\">",
"       Patient information: Chorionic villus sampling (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=see_link\">",
"       Patient information: Prenatal care (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=see_link\">",
"       Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=see_link\">",
"       Patient information: Down syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=see_link\">",
"       Patient information: Chorionic villus sampling (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=see_link\">",
"       Patient information: Amniocentesis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/50/11043?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15528 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11043=[""].join("\n");
var outline_f10_50_11043=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610398\">",
"      What is Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610405\">",
"      What is a screening test for Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610412\">",
"      Which tests can tell for sure if my baby has Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610419\">",
"      Do all women have a screening test for Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610426\">",
"      Are different screening tests available?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610433\">",
"      Why might a woman choose to have a screening test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610440\">",
"      Why might a woman choose not to have a screening test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610447\">",
"      What if my screening test shows that there is a high chance my baby has Down syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610454\">",
"      How do I know which choice is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665610461\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21365\">",
"      Problems caused by Down syndrome",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/56/34690\">",
"       Child with Down syndrome",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/28/14785?source=related_link\">",
"      Patient information: Amniocentesis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/57/42897?source=related_link\">",
"      Patient information: Amniocentesis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/7/2161?source=related_link\">",
"      Patient information: Chorionic villus sampling (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/46/39663?source=related_link\">",
"      Patient information: Chorionic villus sampling (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=related_link\">",
"      Patient information: Down syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/28/34242?source=related_link\">",
"      Patient information: Down syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=related_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/50/2851?source=related_link\">",
"      Patient information: Should I have a screening test for Down syndrome during pregnancy? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_50_11044="Calcium carbonate and magnesium hydroxide: Patient drug information";
var content_f10_50_11044=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium carbonate and magnesium hydroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/59/28598?source=see_link\">",
"     see \"Calcium carbonate and magnesium hydroxide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mi-Acid&trade; Double Strength [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Gelcaps&reg; [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Supreme [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Rolaids&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Rolaids&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used for bone growth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium, magnesium, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If calcium is used as an aid, take with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11298 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-33503A3141-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11044=[""].join("\n");
var outline_f10_50_11044=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012812\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012811\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012816\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012817\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012819\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012814\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012815\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012820\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012821\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/59/28598?source=related_link\">",
"      Calcium carbonate and magnesium hydroxide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_50_11045="Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients";
var content_f10_50_11045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11045/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11045/contributors\">",
"     David E Griffith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11045/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11045/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11045/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11045/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/50/11045/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontuberculous mycobacterial (NTM) infections of the lungs often occur in the context of preexisting lung disease, especially chronic obstructive pulmonary disease (COPD), bronchiectasis, pneumoconiosis, cystic fibrosis, and previous tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As a result, the clinical manifestations of NTM lung disease are often similar to those of the underlying disease. These include cough, fatigue, malaise, fever, weight loss, dyspnea, hemoptysis, and chest discomfort. These same symptoms are also present in patients with NTM lung disease who do not have preexisting pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible presence of NTM lung disease often arises clinically when NTM are identified on sputum culture from a patient under evaluation for tuberculosis. The laboratory findings used to confirm the diagnosis of NTM infection in this setting will be reviewed here. The epidemiology, pathogenesis, and treatment of NTM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=see_link\">",
"     \"Pathogenesis of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEST IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic findings of nontuberculous mycobacterial (NTM) lung disease are variable, depending in part upon the species. Findings consistent with NTM pulmonary infection on chest radiograph or high-resolution computed tomography scan include infiltrates (usually nodular or reticulonodular), cavities, multifocal bronchiectasis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple small nodules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The radiographic pattern of disease can usually be separated into predominantly cavitary versus",
"    <span class=\"nowrap\">",
"     nodular/bronchiectatic.",
"    </span>",
"    Some generalizations can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cavitary disease in the upper lung zones, similar to pulmonary tuberculosis, is seen in approximately 90 percent of patients with M. kansasii infection and perhaps 50 percent of those with Mycobacterium avium complex (MAC) infection. The cavities caused by these organisms tend to have thinner walls and less surrounding parenchymal opacity than those caused by M. tuberculosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At least 50 percent of patients with MAC lung disease have radiographic abnormalities characterized by nodules associated with bronchiectasis or",
"      <span class=\"nowrap\">",
"       nodular/bronchiectatic",
"      </span>",
"      disease. The nodules and bronchiectasis are usually present within the same lobe and occur most frequently in the right middle lobe and lingula [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study, for example, evaluated 100 patients with bronchiectasis, 24 of who also had multiple pulmonary nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/8\">",
"     8",
"    </a>",
"    ]. Among the patients in whom sputum cultures were obtained, a positive culture for MAC was much more likely in those with pulmonary nodules than in those without pulmonary nodules (53 versus 4 percent).",
"   </p>",
"   <p>",
"    High-resolution CT scans of the chest are especially helpful for diagnosing this pattern of MAC lung disease as bronchiectasis and small nodules may not be easily discernible on plain chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/9\">",
"     9",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     nodular/bronchiectatic",
"    </span>",
"    radiographic pattern can also be seen with other NTM pathogens including M. abscessus, M. simiae, and M. kansasii.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solitary nodules and dense consolidation have also been described.",
"     </li>",
"     <li>",
"      Pleural effusions are uncommon, but reactive pleural thickening is frequently seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SKIN TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Species-specific skin test antigens may show considerable cross reactivity and are not commercially available or approved for diagnostic purposes. However, epidemiologic and laboratory studies with well-characterized antigens have shown that dual skin testing with TB versus NTM-derived tuberculins can discriminate between prior NTM and prior TB disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SERODIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been investigation into the utility of serodiagnostic techniques for detecting MAC lung infection and distinguishing it from tuberculosis. In one study, an enzyme immunoassay that measured serum IgA antibody to glycopeptidolipid core antigen specific for MAC was useful for differentiating MAC lung disease from tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/15\">",
"     15",
"    </a>",
"    ]. Further studies are needed to validate this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the lack of diagnostic specificity of chest radiography and skin testing, the diagnosis of NTM lung disease requires microbiologic confirmation (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The possible presence of NTM infection should be considered in a patient with a chronic pulmonary infiltrate with or without a cavity and persistence of one of the aforementioned symptoms. The diagnostic evaluation should consist of smear and culture of at least three separate expectorated sputum specimens obtained in the morning. If the etiology of the patient's symptoms remains uncertain and the infiltrate persists, bronchoscopy with bronchoalveolar lavage (BAL) and or transbronchial biopsies should be performed.",
"   </p>",
"   <p>",
"    Sputum sent for culture of NTM must be chemically decontaminated first in order to eliminate common bacteria and fungi that would overwhelm the culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology of nontuberculous mycobacteria\", section on 'Culture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positive sputum cultures for NTM must be interpreted cautiously since these organisms have variable virulence and can be recovered from the respiratory tract without causing progressive infection (transient infection). In addition, NTM are common in the natural environment and may contaminate laboratory specimens. Tap water especially (liquid or frozen) may contain NTM and contaminate clinical and laboratory specimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=see_link\">",
"     \"Epidemiology of nontuberculous mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NTM frequently occurs in the context of underlying lung disease, which can also cause symptoms. As a result, the distinction between transient infection or contamination and true infection is sometimes difficult. Fortunately, most lung disease caused by NTM is indolent so that careful assessment over time is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to address these difficulties, the American Thoracic Society (ATS) and Infectious Disease Society of America (IDSA) have jointly established specific criteria for the diagnosis of NTM lung disease (",
"    <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/4\">",
"     4",
"    </a>",
"    ]. In symptomatic patients with evidence of pulmonary disease by imaging studies and with other processes such as fungal disease, malignancy, and tuberculosis excluded, the diagnostic criteria to support NTM clinical infection as opposed to colonization of secretions includes one of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive culture results from at least two separate expectorated sputum samples (regardless of AFB smear result)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive culture result from at least one bronchial wash or lavage (regardless of AFB smear result)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biopsy showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture positive for NTM",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive culture from pleural fluid or any other normally sterile extrapulmonary site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolation of M. gordonae, M. mucogenicum, M. nonchromogenicum, M. haemophilum, M. flavescens, M. gastri, M. terrae, or M. triviale indicates probable colonization or contamination. These organisms are generally not pathogenic for humans except in the context of severe cellular immunodeficiency, such as AIDS. Expert consultation should be obtained when NTM are recovered that are either infrequently encountered or that usually represent environmental contamination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/4\">",
"     4",
"    </a>",
"    ]. Making a diagnosis of NTM infection may not necessitate the initiation of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Isolation of NTM in symptomatic patients, regardless of whether the above",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    criteria are met, may itself be a marker for poor prognosis. In a retrospective review of patients with at least one positive culture for NTM (predominantly from pulmonary specimens), four-year mortality rates were high and not significantly different among the 61 patients who met and the 59 patients who did not meet",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    criteria for NTM infection (28 versus 41 percent mortality); a similar percentage of the patients who were treated for NTM did and did not meet criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11045/abstract/16\">",
"     16",
"    </a>",
"    ]. Prognosis was most related to the severity of underlying diseases, which was greater among patients who did not meet criteria. However, determining the prognostic impact of the current diagnostic guidelines is complicated, and the diagnostic criteria remain useful for determining which patients are likely to have significant NTM lung disease and should be considered candidates for therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87182791\">",
"    <span class=\"h1\">",
"     NUCLEIC ACID PROBES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Highly accurate nucleic acid probes (Accuprobe, GenProbe, Inc) are commercially available that can identify Mycobacterium avium complex (MAC) isolates within one day after recognizable growth is evident, a technique currently used by most reference laboratories. A similar nucleic acid probe is also available for the identification of M. kansasii.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633801088\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nontuberculous mycobacterial (NTM) infections of the lungs often occur in the context of preexisting lung disease, especially chronic obstructive pulmonary disease (COPD), bronchiectasis, pneumoconiosis, cystic fibrosis, and previous tuberculosis. As a result, the clinical manifestations of NTM lung disease are often similar to those of the underlying disease. These include cough, fatigue, malaise, fever, weight loss, dyspnea, hemoptysis, and chest discomfort. These same symptoms are also present in patients with NTM lung disease who do not have preexisting pulmonary disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The radiographic findings of nontuberculous mycobacterial (NTM) lung disease are variable, depending in part upon the species. Findings consistent with NTM pulmonary infection on chest radiograph or high-resolution computed tomography scan include infiltrates (usually nodular or reticulonodular), cavities, multifocal bronchiectasis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      multiple small nodules. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chest imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the lack of diagnostic specificity of chest radiography and skin testing, the diagnosis of NTM lung disease requires microbiologic confirmation (",
"      <a class=\"graphic graphic_table graphicRef61404 \" href=\"UTD.htm?10/48/11020\">",
"       table 1",
"      </a>",
"      ). The possible presence of NTM infection should be considered in a patient with a chronic pulmonary infiltrate with or without a cavity and persistence of symptoms. The diagnostic evaluation should consist of smear and culture of at least three separate expectorated sputum specimens obtained in the morning. If the etiology of the patient's symptoms remains uncertain and the infiltrate persists, bronchoscopy with bronchoalveolar lavage (BAL) and or transbronchial biopsies should be performed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Highly accurate nucleic acid probes are commercially available that can identify Mycobacterium avium complex (MAC) isolates within one day after recognizable growth is evident, a technique currently used by most reference laboratories. A similar nucleic acid probe is also available for the identification of M. kansasii. (See",
"      <a class=\"local\" href=\"#H87182791\">",
"       'Nucleic acid probes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Chapman JS. The Atypical Mycobacteria and Human Mycobacteriosis, 16th Ed, Plenum, New York 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/2\">",
"      Yeager H Jr, Raleigh JW. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis 1973; 108:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/3\">",
"      Davidson PT. The diagnosis and management of disease caused by M. avium complex, M. kansasii, and other mycobacteria. Clin Chest Med 1989; 10:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/4\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/5\">",
"      Woodring JH, Vandiviere HM. Pulmonary disease caused by nontuberculous mycobacteria. J Thorac Imaging 1990; 5:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/6\">",
"      Christensen EE, Dietz GW, Ahn CH, et al. Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M kansasii, and M intracellularis infections. Chest 1981; 80:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/7\">",
"      Levin DL. Radiology of pulmonary Mycobacterium avium-intracellulare complex. Clin Chest Med 2002; 23:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/8\">",
"      Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994; 105:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/9\">",
"      Koh WJ, Lee KS, Kwon OJ, et al. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology 2005; 235:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/10\">",
"      Edwards LB, Acquaviva FA, Livesay VT, et al. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969; 99:Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/11\">",
"      von Reyn CF, Green PA, McCormick D, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis. Clin Infect Dis 1994; 19:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/12\">",
"      Huebner RE, Schein MF, Cauthen GM, et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am Rev Respir Dis 1992; 145:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/13\">",
"      von Reyn CF, Williams DE, Horsburgh CR Jr, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M. avium complex from pulmonary disease due to Mycobacterium tuberculosis. J Infect Dis 1998; 177:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/14\">",
"      von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001; 5:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/15\">",
"      Kitada S, Kobayashi K, Ichiyama S, et al. Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. Am J Respir Crit Care Med 2008; 177:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11045/abstract/16\">",
"      Kotilainen H, Valtonen V, Tukiainen P, et al. Prognostic value of American Thoracic Society criteria for non-tuberculous mycobacterial disease: a retrospective analysis of 120 cases with four years of follow-up. Scand J Infect Dis 2013; 45:194.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5346 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11045=[""].join("\n");
var outline_f10_50_11045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1633801088\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEST IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SKIN TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SERODIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87182791\">",
"      NUCLEIC ACID PROBES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633801088\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5346|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/48/11020\" title=\"table 1\">",
"      Criteria for NTM diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24089?source=related_link\">",
"      Epidemiology of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/35/5687?source=related_link\">",
"      Microbiology of nontuberculous mycobacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=related_link\">",
"      Pathogenesis of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_50_11046="Diagnosis and treatment of diphtheria";
var content_f10_50_11046=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of diphtheria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11046/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11046/contributors\">",
"     Luis F Barroso, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11046/contributors\">",
"     P Samuel Pegram, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11046/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11046/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11046/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11046/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/50/11046/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria is an infectious disease caused by the gram-positive bacillus Corynebacterium diphtheriae. Infection may lead to respiratory disease, cutaneous disease, or an asymptomatic carrier state. The word diphtheria comes from the Greek word for leather, which refers to the tough pharyngeal membrane that is the clinical hallmark of infection.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of diphtheria will be reviewed here. The epidemiology, pathophysiology, clinical manifestations, and prevention of this infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H19#H19\">",
"     \"Standard immunizations for children and adolescents\", section on 'Diphtheria, tetanus, and/or pertussis vaccines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of diphtheria should be considered in the setting of relevant clinical manifestations (sore throat, malaise, cervical lymphadenopathy, and low grade fever) together with appropriate epidemiologic risk factors. Mild pharyngeal erythema typically progresses to areas of white exudate; these coalesce to form an adherent gray pseudomembrane that bleeds with scraping. Clinical suspicion for diphtheria should be further heightened in the setting of adherent pharyngeal, palatal, or nasal membranes, systemic toxicity, hoarseness, stridor, palatal paralysis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serosanguineous nasal discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive diagnosis of diphtheria requires culture of C. diphtheriae from respiratory tract secretions or cutaneous lesions, and a positive toxin assay. Routine laboratory results are usually non-specific and may include a moderately elevated white blood cell count and proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures should be obtained from the throat and nose including a portion of the membrane (if possible), and material from beneath the membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/2\">",
"     2",
"    </a>",
"    ]. Special culture media (Loffler's or Tindale's) are required; the microbiology laboratory should be notified of the suspected diagnosis so that the specimen is plated on appropriate media. Transport to the laboratory must be accomplished quickly since the media must be inoculated promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A presumptive diagnosis of C. diphtheriae can be made by identifying gram-positive rods in a \"Chinese character\" distribution on Gram stain, black colonies with halos on Tindale's media, and metachromatic granules on Loffler's media (",
"    <a class=\"graphic graphic_picture graphicRef73771 \" href=\"UTD.htm?39/26/40352\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the organism is presumptively identified, biochemical testing can be performed to confirm C. diphtheriae; it is catalase positive, urease negative, cystinase positive, and pyrazinamidase negative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Toxin detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for toxin production must be performed to differentiate toxigenic from non-toxigenic strains of C. diphtheriae. If clinical suspicion for diphtheria is high, antitoxin should be administered promptly prior to confirmation of toxin production, which may take several days depending upon the method used.",
"   </p>",
"   <p>",
"    Toxin production can be demonstrated by an in vitro assay that detects development of an immunoprecipitin band on antitoxin-impregnated filter paper laid over an agar culture of the organism (Elek test) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/6\">",
"     6",
"    </a>",
"    ]. The test requires quality control of reagents and a standardized procedure, so is best performed in a reference laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) testing for the A subunit of the diphtheria toxin gene can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/6\">",
"     6",
"    </a>",
"    ]. A positive PCR for the diphtheria toxin gene demonstrates the presence of the gene but does not indicate whether toxin is being produced; therefore positive PCR results must be confirmed by culture to establish the presence of clinical disease due to a toxigenic strain of C. diphtheriae [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/4\">",
"     4",
"    </a>",
"    ]. A negative PCR is helpful in excluding the diagnosis of diphtheria. PCR can be performed on colonies extracted from a plate and or on clinical specimens. One group reported successful PCR testing on a formalin-fixed throat swab, which would not be suitable for culturing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rapid enzyme immunoassay (EIA) for the detection of diphtheria toxin production has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/8\">",
"     8",
"    </a>",
"    ]. In a study of 245 mixed strains of Corynebacterium, comparable results were observed with EIA and Elek though EIA testing was faster (3 versus 24 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Definitive cases of diphtheria in the United States should be reported immediately to the state health department and the Centers for Disease Control and Prevention (CDC), and culture material should be sent to the CDC for confirmation. The CDC Pertussis and Diphtheria Laboratory offers culture, toxigenicity testing, PCR, and serology.&nbsp;For detailed information on specimen collection and shipping, and to arrange PCR testing, the laboratory can be contacted by phone (404-639-1231) or fax (404-639-4421). In other countries, reports should be submitted to the WHO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of pharyngitis includes infectious mononucleosis, group A streptococcal tonsillopharyngitis, and epiglottitis. Pharyngitis due to viruses, Vincent's angina, Corynebacterium ulcerans, Corynebacterium hemolyticum, and severe oral candidiasis can also be confused with diphtheria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/9\">",
"     9",
"    </a>",
"    ]. Toxigenic strains of C. ulcerans produce a diphtheria toxin similar to that produced by toxigenic strains of C. diphtheriae, underscoring the importance of early treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of respiratory diphtheria consists of antibiotic therapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"     diphtheria antitoxin",
"    </a>",
"    for severe cases. Careful airway management is important due to risk of airway obstruction. In addition, patients should be monitored with serial electrocardiograms and measurements of cardiac enzymes that reflect the intensity of myocardial damage. Neurologic status should also be monitored carefully. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\", section on 'Systemic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with respiratory diphtheria should be placed on respiratory droplet isolation for respiratory tract disease and contact precautions for cutaneous disease. Isolation should be continued until two consecutive cultures taken at least 24 hours apart are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Follow up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatment of cutaneous diphtheria consists of antibiotic therapy; antitoxin is not usually needed given lack of pseudomembranes or cardiac involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antitoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"     Diphtheria antitoxin",
"    </a>",
"    is a hyperimmune antiserum produced in horses that binds to and inactivates the diphtheria toxin. Antitoxin was first shown to reduce mortality from 7 to 2.5 percent in a controlled trial published in 1898 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/12\">",
"     12",
"    </a>",
"    ]. Antitoxin is only effective before toxin enters the cell and therefore must be administered early [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/3\">",
"     3",
"    </a>",
"    ]. Antitoxin is not commercially available in the United States, but may be obtained from the CDC; the CDC also provides telephone consultation for diagnosis and treatment questions (1-404-639-2889).",
"   </p>",
"   <p>",
"    There is an approximately 10 percent risk of hypersensitivity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum sickness. Prior allergy history should be elicited and a scratch test dose of 1:100 dilution should be administered. The test dose may be followed by 0.02 mL of 1:1000 dilution of antitoxin and then the therapeutic dose [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/13\">",
"     13",
"    </a>",
"    ]. Epinephrine should be immediately available because of the potential for anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of antitoxin depends upon the site and severity of infection. The American Academy of Pediatrics recommends 20,000 to 40,000 units for",
"    <span class=\"nowrap\">",
"     pharyngeal/laryngeal",
"    </span>",
"    disease of &lt;48 hours duration, 40,000 to 60,000 units for nasopharyngeal disease, and 80,000 to 120,000 units for &gt;3 days of illness or diffuse neck swelling (\"bull-neck\") [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/11\">",
"     11",
"    </a>",
"    ]. The dose should be administered intravenously over 60 minutes in order to inactivate toxin rapidly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy has three major benefits: it kills the organism and thus prevents further toxin from being formed, it slows the spread of local infection and it reduces transmission.",
"   </p>",
"   <p>",
"    The antibiotics of choice are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 mg four times daily for 14 days) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (25,000 to 50,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    to a maximum of 1.2 million units IV every 12 hours until the patient can take oral medicine) followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    (250 mg four times daily) for a total treatment course of 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Erythromycin has been favored given reports of greater efficacy compared with penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], although one report of 71 patients noted that 21 percent of cases had positive cultures for C. diphtheriae two weeks after completion of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/17\">",
"     17",
"    </a>",
"    ]. For this reason, repeat cultures should be obtained at least two weeks after completing therapy to ensure eradication of the organism.",
"   </p>",
"   <p>",
"    In vitro, C. diphtheriae is usually susceptible to multiple other agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , quinolones, tetracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In the setting of antibiotic resistance, vancomycin or linezolid are reasonable alternative antibiotic choices; antibiogram results should be used to tailor therapy to individual patient circumstances.",
"   </p>",
"   <p>",
"    Respiratory failure due to airway compromise is a major complication of diphtheria and is an important cause of mortality. In severely ill patients with signs of extensive pseudomembrane formation, stridor, or the toxic &ldquo;bull neck&rdquo; of diphtheria, respiratory failure should be anticipated and managed aggressively. Intubation may help to protect the airway, although frequently this is a difficult procedure in patients with diphtheria due to extensive airway edema and mucosal friability; there is also potential for inadvertent dislodging of the pseudomembrane. Ideally, intubation should be performed by experienced providers in the setting of operative backup for tracheostomy for definitive airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Follow up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow up cultures should be performed at 24 to 48 hours and two weeks following infection to document clearance. Isolation should be continued until two consecutive cultures taken at least 24 hours apart are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients should receive diphtheria toxoid immunization during their convalescence since natural infection does not induce immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contact prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close contacts include household members and other persons with a history of direct contact with a case-patient (eg, caretakers, relatives, or friends who regularly visit the home) as well as medical staff exposed to oral or respiratory secretions of a case-patient. Close contacts need to be identified, cultured, and considered for antimicrobial prophylaxis (",
"    <a class=\"graphic graphic_algorithm graphicRef68859 \" href=\"UTD.htm?6/14/6369\">",
"     algorithm 1",
"    </a>",
"    ). If immunizations are not current, diphtheria toxoid immunization should be administered. After cultures have been obtained, contacts should be treated with a single dose of benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (600,000 units IM for individuals &lt;6 years of age and 1.2 million units IM for individuals &ge;6 years of age) or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 mg four times daily for 7 to 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=see_link\">",
"     \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=see_link&amp;anchor=H11#H11\">",
"     \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Vaccine schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among 676 hospitalized patients with diphtheria in the Kyrgyz Republic, the overall mortality was 2.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11046/abstract/21\">",
"     21",
"    </a>",
"    ]. Of the 19 patients who died, 79 percent presented to the hospital &ge;4 days after onset of symptoms. The mortality rate was higher among the 151 patients with myocarditis than among those without myocarditis (7 versus 2 percent). In addition, the mortality rate was higher in patients &lt;15 years of age than patients &ge;15 years of age (5.5 versus 1.7 percent)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15943994\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of diphtheria should be considered in the setting of relevant clinical manifestations (sore throat, malaise, cervical lymphadenopathy, and low grade fever) together with appropriate epidemiologic risk factors. Definitive diagnosis of diphtheria requires culture of C. diphtheriae from respiratory tract secretions or cutaneous lesions, and a positive toxin assay. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cultures should be obtained from the throat and nose including a portion of the membrane (if possible), and material from beneath the membrane. Special culture media are required; the microbiology laboratory should be notified of the suspected diagnosis so that the specimen is plated on appropriate media. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for toxin production must be performed to differentiate toxigenic from non-toxigenic strains of C. diphtheriae. If clinical suspicion for diphtheria is high, antitoxin should be administered promptly prior to confirmation of toxin production, which may take several days depending upon the method used. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxin detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of respiratory diphtheria consists of antibiotic therapy and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/15/21745?source=see_link\">",
"       diphtheria antitoxin",
"      </a>",
"      . Antitoxin can induce serum sickness; precautions and dosing are outlined above. We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      or penicillin for treatment of diphtheria (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Dosing is outlined above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antitoxin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful airway management is important due to risk of airway obstruction. Patients should be placed on respiratory droplet isolation for respiratory tract disease and contact precautions for cutaneous disease. Patients should be monitored with serial electrocardiograms and measurements of cardiac enzymes that reflect the intensity of myocardial damage. Neurologic status should also be monitored carefully. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Follow up cultures should be performed at 24 to 48 hours and two weeks following infection ensure eradication of the organism. Isolation should be continued until two consecutive cultures taken at least 24 hours apart are negative. Patients should receive diphtheria toxoid immunization during their convalescence since natural infection does not induce immunity. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Follow up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Close contacts need to be identified, cultured, and considered for antimicrobial prophylaxis (",
"      <a class=\"graphic graphic_algorithm graphicRef68859 \" href=\"UTD.htm?6/14/6369\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Contact prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/1\">",
"      Farizo KM, Strebel PM, Chen RT, et al. Fatal respiratory disease due to Corynebacterium diphtheriae: case report and review of guidelines for management, investigation, and control. Clin Infect Dis 1993; 16:59.",
"     </a>",
"    </li>",
"    <li>",
"     Clarridge JE, Popovic T, Inzana TJ. Diphtheria and other corynebacterial and coryneform infections. In: Topley and Wilson's Microbiology and Microbial Infections, Hausler WJ, Sussman M (Eds), Oxford University Press, New York City 1998. Vol 3, p.347.",
"    </li>",
"    <li>",
"     MacGregor RR. Corynebacterium diphtheriae. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2457.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/4\">",
"      Efstratiou A, Engler KH, Mazurova IK, et al. Current approaches to the laboratory diagnosis of diphtheria. J Infect Dis 2000; 181 Suppl 1:S138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/5\">",
"      Colman G, Weaver E, Efstratiou A. Screening tests for pathogenic corynebacteria. J Clin Pathol 1992; 45:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/6\">",
"      Efstratiou A, Engler KH, Dawes CS, Sesardic D. Comparison of phenotypic and genotypic methods for detection of diphtheria toxin among isolates of pathogenic corynebacteria. J Clin Microbiol 1998; 36:3173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/7\">",
"      Komiya T, Shibata N, Ito M, et al. Retrospective diagnosis of diphtheria by detection of the Corynebacterium diphtheriae tox gene in a formaldehyde-fixed throat swab using PCR and sequencing analysis. J Clin Microbiol 2000; 38:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/8\">",
"      Engler KH, Efstratiou A. Rapid enzyme immunoassay for determination of toxigenicity among clinical isolates of corynebacteria. J Clin Microbiol 2000; 38:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/9\">",
"      Kovatch AL, Schuit KE, Michaels RH. Corynebacterium hemolyticum peritonsillar abscess mimicking diphtheria. JAMA 1983; 249:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/10\">",
"      Tiwari TS, Golaz A, Yu DT, et al. Investigations of 2 cases of diphtheria-like illness due to toxigenic Corynebacterium ulcerans. Clin Infect Dis 2008; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Diphtheria. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/12\">",
"      Park WH, Atkinson JP. THE RELATION OF THE TOXICITY OF DIPHTHERIA TOXIN TO ITS NEUTRALIZING VALUE UPON ANTITOXIN AT DIFFERENT STAGES IN THE GROWTH OF CULTURE. J Exp Med 1898; 3:513.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Antibodies of animal origin (animal antisera). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/14\">",
"      Kneen R, Pham NG, Solomon T, et al. Penicillin vs. erythromycin in the treatment of diphtheria. Clin Infect Dis 1998; 27:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/15\">",
"      Zalma VM, Older JJ, Brooks GF. The Austin, Texas, diphtheria outbreak. Clinical and epidemiological aspects. JAMA 1970; 211:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/16\">",
"      McCloskey RV, Eller JJ, Green M, et al. The 1970 epidemic of diphtheria in San Antonio. Ann Intern Med 1971; 75:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/17\">",
"      Miller LW, Bickham S, Jones WL, et al. Diphtheria carriers and the effect of erythromycin therapy. Antimicrob Agents Chemother 1974; 6:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/18\">",
"      Zasada AA, Baczewska-Rej M, Wardak S. An increase in non-toxigenic Corynebacterium diphtheriae infections in Poland--molecular epidemiology and antimicrobial susceptibility of strains isolated from past outbreaks and those currently circulating in Poland. Int J Infect Dis 2010; 14:e907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/19\">",
"      Engler KH, Warner M, George RC. In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae. J Antimicrob Chemother 2001; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/20\">",
"      Jayashree M, Shruthi N, Singhi S. Predictors of outcome in patients with diphtheria receiving intensive care. Indian Pediatr 2006; 43:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11046/abstract/21\">",
"      Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic, 1995. J Infect Dis 2000; 181 Suppl 1:S110.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8047 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11046=[""].join("\n");
var outline_f10_50_11046=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15943994\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Toxin detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antitoxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Follow up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contact prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15943994\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8047\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8047|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?6/14/6369\" title=\"algorithm 1\">",
"      Contacts diphtheria protocol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8047|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/26/40352\" title=\"picture 1\">",
"      C diphtheriae photomicrograph",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_50_11047="Pneumococcal immunization in HIV-infected patients";
var content_f10_50_11047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pneumococcal immunization in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11047/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11047/contributors\">",
"     Patricia L Hibberd, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11047/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11047/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11047/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11047/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/50/11047/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H272977\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal infections, including pneumonia and invasive disease such as bacteremia and meningitis, have been a major source of morbidity and mortality since the beginning of the HIV epidemic, leading many experts to endorse use of pneumococcal vaccine for primary prevention in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the efficacy of pneumococcal vaccine in this patient population has been debated for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, pneumococcal vaccines are serotype-specific, so efficacy will also vary depending on the prevalent serotypes within the community.",
"   </p>",
"   <p>",
"    This topic addresses data on the use of polysaccharide and conjugate pneumococcal vaccines in HIV-infected patients and suggestions for primary prevention. Data on the use of pneumococcal vaccines in the immunocompetent host are found elsewhere. Advice on the use of other vaccines in HIV-infected patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=see_link\">",
"     \"Prevention of hepatitis B virus infection in the HIV-infected adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11160230\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF PNEUMOCOCCAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal pneumonia and meningitis are leading causes of morbidity and mortality among HIV-infected patients worldwide and treatment is complicated by the increasing incidence of drug-resistant pneumococcal strains [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The overall incidence of invasive pneumococcal disease was 677 cases per 100,000 person-years in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/3\">",
"     3",
"    </a>",
"    ]. The case fatality rate of invasive disease ranges from 8 percent with pneumococcal bacteremia to 50 percent with meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study performed in San Francisco, prior to the era of potent antiretroviral therapy (ART), found that the rates of pneumococcal bacteremia were approximately 100-fold greater in HIV-infected patients compared with those who were not infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, recurrent invasive pneumococcal disease is common, occurring in up to 25 percent of patients within a year after the initial episode [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273053\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factor for developing pneumococcal infections is the level of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In one trial of pneumococcal vaccine efficacy, the vast majority of HIV-infected patients who developed invasive pneumococcal disease had a CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B cell immunity, which is critical for protection against encapsulated organisms, is impaired in patients with late-stage AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. Some in vitro data suggest that these defects in B cell immunity begin early in HIV infection and may be related to immune activation and the production of proinflammatory cytokines during untreated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/4\">",
"     4",
"    </a>",
"    ]. High levels of HIV RNA have also been associated with increased risk of pneumococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/8,13,14\">",
"     8,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational data suggest that other risk factors for invasive pneumococcal infection in HIV-infected patients include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/5,8-10,15\">",
"     5,8-10,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cirrhosis",
"     </li>",
"     <li>",
"      Low serum albumin",
"     </li>",
"     <li>",
"      Heavy alcohol use",
"     </li>",
"     <li>",
"      Injection drug use",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Previous episodes of pneumonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, receipt of ART and antibiotic prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ), which is given for the prevention of pneumocystis infection in patients with advanced immunosuppression, also protects against pneumococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/9,13,15-17\">",
"     9,13,15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273655\">",
"    <span class=\"h1\">",
"     AVAILABLE VACCINE FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of pneumococcal vaccine are available: the 23-valent polysaccharide vaccine (ie, PPSV-23) and a 13-valent conjugate vaccine (ie, PCV-13), which has replaced the 7-valent conjugate vaccine (PCV-7).",
"   </p>",
"   <p>",
"    The PCV-13 vaccine extends coverage of the prior PCV-7 vaccine by including antigens to six additional serotypes of pneumococcus, including the 19A serotype, which has increased in frequency in the United States since the introduction of PCV-7 immunization in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A full discussion of these vaccines and their use in HIV-uninfected persons is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11160237\">",
"    <span class=\"h1\">",
"     EFFICACY AND IMMUNOGENICITY OF PNEUMOCOCCAL VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal immunization has been recommended for HIV-infected patients in developed countries since the mid 1990s, based on the high incidence of invasive disease in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/20\">",
"     20",
"    </a>",
"    ]. The only clinical trials evaluating the efficacy of pneumococcal vaccine in HIV-infected patients have been conducted in resource-limited settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273686\">",
"    <span class=\"h2\">",
"     Polysaccharide vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sole clinical trial that examined the efficacy of polysaccharide vaccine was conducted in 1312 HIV-infected adults over three years of follow-up, starting in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Participants were randomly assigned to one dose of polysaccharide vaccine or a placebo inoculation. Invasive pneumococcal disease with bacteremia occurred in only 25 persons (15 in the vaccine arm and 10 in the placebo arm; HR 1.47; 95% CI 0.7-3.3). Twenty-two isolates (88 percent) were of vaccine-specific serotypes (15 versus 7 events in the vaccine arm versus the placebo arm, respectively; HR 2.1; 95% CI 0.9-5.2). Unexpectedly, the number of cases of all-cause pneumonia was significant higher in the intervention arm, although mortality did not differ.",
"   </p>",
"   <p>",
"    Postimmunization titers doubled in only 40 percent of those assigned to the intervention arm. The authors concluded that although pneumococcal immunization with polysaccharide vaccine was well tolerated, the vaccine did not confer protection. Limitations of the trial included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall low number of cases of invasive pneumococcal disease",
"     </li>",
"     <li>",
"      The absence of antiretroviral therapy (ART), which probably contributed to the high rates of overall mortality seen in this trial (ie, 53 percent)",
"     </li>",
"     <li>",
"      Suboptimal vaccine immunogenicity since approximately 45 percent of the patients had advanced immunosuppression (eg, CD4 cell count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple observational studies have been performed in the developed world to assess the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    against all cause pneumonia, pneumococcal pneumonia, and invasive pneumococcal disease (eg, bacteremia). A systematic review of these data suggests that most of the studies support a benefit of polysaccharide vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/2\">",
"     2",
"    </a>",
"    ]. However, because of design flaws the available clinical evidence provides only moderate support for the efficacy of pneumococcal polysaccharide vaccine in HIV-infected adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibody responses to the 23-valent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    in HIV-infected patients are lower than those achieved in healthy subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Rates of seroconversion are generally lower in patients with CD4 counts below 300",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/25-27\">",
"     25-27",
"    </a>",
"    ], although patients on ART achieve a more durable antibody response than untreated patients, independent of the baseline CD4 cell count prior to immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273755\">",
"    <span class=\"h2\">",
"     Conjugate vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no clinical data on the use of PCV-13 in HIV-infected adults, clinical trials have demonstrated significant efficacy and immunogenicity of the 7-valent conjugate vaccine among HIV-infected adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/11,29\">",
"     11,29",
"    </a>",
"    ]. There are no trials comparing polysaccharide vaccines and conjugate vaccines in HIV-infected patients.",
"   </p>",
"   <p>",
"    In one double-blind clinical trial conducted in Malawi, the efficacy of pneumococcal immunization for secondary prevention was evaluated among 496 patients with a history of documented invasive pneumococcal disease; 88 percent also had underlying HIV infection, but only 13 percent of the HIV-infected patients were taking ART [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/11\">",
"     11",
"    </a>",
"    ]. Two doses of PCV-7 were administered four weeks apart in the intervention arm. The primary endpoint was an episode of pneumococcal disease caused by one of the vaccine serotypes; furthermore, disease related to serotype 6A was also included, based on data showing a cross-protective effect of the vaccine. Over a median follow-up of approximately 14 months, the following results were demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower number of episodes of pneumococcal disease (caused by vaccine serotypes or the 6A serotype), occurred in the vaccine group compared with the placebo group (5 versus 19, respectively) for an estimated overall vaccine efficacy of 74 percent among HIV-infected patients (95% CI, 30-90 percent).",
"     </li>",
"     <li>",
"      Vaccine efficacy, estimated at 85 percent in the first year, declined to 25 percent in the second year, despite an increase in the number of HIV patients receiving ART as the trial progressed.",
"     </li>",
"     <li>",
"      There was no significant difference in all-cause mortality or mortality associated with pneumococcal disease between the intervention and placebo groups.",
"     </li>",
"     <li>",
"      HIV RNA levels were not measured after immunization to address possible upregulation of HIV infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a second clinical trial, 212 HIV-infected French patients with CD4 cell counts of 200 to 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and plasma HIV RNA &lt;50,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    were randomly assigned to receive either PCV-7 followed by a boost with 23-valent polysaccharide vaccine (PPSV-23) four weeks later or PPSV-23 alone at week four [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/29\">",
"     29",
"    </a>",
"    ]. The proportion of immunologic responders to pneumococcal serotypes, shared by both vaccines, was examined. Those patients in the &ldquo;prime-boost&rdquo; strategy arm had a greater frequency and breadth of serologic responses to Streptococcal pneumoniae polysaccharide antigens at eight weeks than patients who received PPSV alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/29\">",
"     29",
"    </a>",
"    ]. Early differences in IgG titers persisted at 24 weeks of follow-up with this prime-boost strategy. There were no data on clinical efficacy reported in this trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87043776\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, there are no head to head trials comparing polysaccharide vaccines and conjugate vaccines in HIV-infected patients. However, there are promising data regarding a prime-boost effect of PCV-7 followed by PPSV-23 on inducing and maintaining protective immunity. In addition, the Malawi trial suggests efficacy of PCV-7 in reducing pneumococcal disease, although efficacy declined over time in this mainly untreated HIV-infected patient population with advanced immunosuppression.",
"   </p>",
"   <p>",
"    ART is likely to be of equal importance to immunization in protection against pneumococcal disease through the preservation of immune function and subsequent protection against encapsulated organisms.",
"   </p>",
"   <p>",
"    Preliminary data suggest that the use of adjuvants may be a promising tool to help improve overall vaccine immunogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273895\">",
"    <span class=\"h1\">",
"     VACCINE RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations by the Advisory Committee on Immunization Practices (ACIP) for the HIV-infected patient are influenced by clinical trial data on vaccine efficacy and immunogenicity in HIV-uninfected adults.",
"   </p>",
"   <p>",
"    In December 2011, the US Food and Drug Administration (FDA) approved pneumococcal conjugate vaccine (PCV-13) for use in adults &ge;50 years of age based upon safety and immunogenicity data in more than 6000 HIV-uninfected adults; these data showed that PCV-13 induced antibody responses that were either comparable to or higher than the responses induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV-23) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. PCV-13 also appears to have a similar safety profile as PPSV-23 (eg, pain at the injection site).",
"   </p>",
"   <p>",
"    However, PCV-13 has",
"    <strong>",
"     not",
"    </strong>",
"    yet been recommended by the United States Advisory Committee on Immunization Practices (ACIP) for use in healthy adults. This decision was based upon the lack of data demonstrating: a) clinical efficacy against pneumococcal pneumonia in adults and b) impact of childhood PCV-13 vaccination on the incidence of pneumococcal disease in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/33\">",
"     33",
"    </a>",
"    ]. A clinical trial comparing the clinical efficacy of pneumococcal conjugate vaccine (PCV-13) versus placebo is currently enrolling 85,000 adults &ge;65 years of age in the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in June 2012, the ACIP voted to recommend PCV-13 for use in individuals aged 19 or older with HIV infection and other immunocompromising conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/35\">",
"     35",
"    </a>",
"    ]. Although there are no data to specifically address the efficacy and immunogenicity of the 13-valent conjugate vaccine among HIV-infected patients, these recommendations were likely influenced by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy data with pneumococcal conjugate vaccine valent-7, which showed short-term protection in HIV-infected patients with a history of invasive pneumococcal disease",
"     </li>",
"     <li>",
"      The expected comparable efficacy of the expanded pneumococcal conjugate vaccine (PCV-13) in HIV-infected patients compared to the 7-valent vaccine",
"     </li>",
"     <li>",
"      The benefit of additional serotype coverage afforded by the 13-valent conjugate vaccine, including serotype 19A, which is increasing in prevalence in the United States",
"     </li>",
"     <li>",
"      The high incidence and mortality of invasive pneumococcal infection",
"     </li>",
"     <li>",
"      The safety profile of the vaccine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273914\">",
"    <span class=\"h1\">",
"     VACCINE ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing schedule of pneumococcal vaccine depends on the patient&rsquo;s immunization history:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have previously received one or more doses of PPSV-23, PCV-13 should be given one or more years after the last PPSV-23 dose was received.",
"     </li>",
"     <li>",
"      Patients who have not previously received PCV-13 or PPSV-23 should receive a single dose of PCV-13 followed by a dose of PPSV-23 at least eight weeks later (ie, the &ldquo;prime-boost&rdquo; strategy) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11160265\">",
"    <span class=\"h1\">",
"     WHEN TO IMMUNIZE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC), National Institutes of Health, and the HIV Medicine Association recommend administering pneumococcal vaccine to adults and children with CD4 counts greater than 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    as soon as HIV infection is diagnosed (providing that they have not had the vaccine during the previous five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/36\">",
"     36",
"    </a>",
"    ]. If the initial immunization was given when the CD4 count was less than 200",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    the guidelines suggest considering revaccination if antiretroviral therapy (ART) increases the CD4 count to 200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or more. We expect that subsequent guidelines on the use of pneumococcal conjugate vaccine (PCV-13) will be similar. In the era before potent ART, administration of pneumococcal vaccine was associated with transient increases in viral load, although the clinical importance of this finding is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11047/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer to administer pneumococcal conjugate vaccine to patients who have achieved viral suppression and some degree of immune recovery (minimum CD4 count of 200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    on ART. Data in other vaccines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    ) suggest that vaccine immunogenicity is improved in the setting of viral suppression. In addition, viral suppression on ART decreases the theoretical possibility that immunization may lead to upregulation of HIV.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=see_link&amp;anchor=H2121208#H2121208\">",
"     \"Prevention of hepatitis B virus infection in the HIV-infected adult\", section on 'Risk factors for decreased vaccine response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87043721\">",
"    <span class=\"h1\">",
"     ROLE OF PROPHYLAXIS AGAINST PNEUMOCYSTIS AND PNEUMOCOCCAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CD4 cell counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    should be given",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for pneumocystis prophylaxis; this intervention also decreases the risk of invasive pneumococcal infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link&amp;anchor=H6#H6\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\", section on 'Pneumocystis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274016\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysaccharide vaccine and conjugate vaccines are both well tolerated. The major adverse event is soreness at the injection site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274093\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumococcal pneumonia and meningitis are leading causes of morbidity and mortality among HIV-infected patients worldwide and treatment is complicated by the increasing incidence of drug-resistant pneumococcal strains. The most important risk factor for developing pneumococcal infections is the level of immunosuppression (eg, CD4 count &lt;200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H11160230\">",
"       'Epidemiology of pneumococcal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Available pneumococcal vaccine formulations include the 23-valent polysaccharide vaccine (ie, PPSV-23) and the 13-valent conjugate vaccine (ie, PCV-13), which has replaced the 7-valent conjugate vaccine. The PCV-13 vaccine affords protection against additional serotypes of pneumococcus that cause invasive disease. (See",
"      <a class=\"local\" href=\"#H273655\">",
"       'Available vaccine formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococcal immunization has been advised for HIV-infected patients in developed countries since the mid-1990s, based on the high incidence of invasive disease in this patient population. A systematic review of mainly observational data suggests moderate efficacy of pneumococcal vaccine among HIV-infected patients. Immunogenicity is lower among HIV-infected patients compared to healthy subjects, although HIV-infected patients taking antiretroviral therapy (ART) achieve higher vaccine-specific antibody titers than those who are not taking ART. Combination ART also decreases overall mortality. (See",
"      <a class=\"local\" href=\"#H11160237\">",
"       'Efficacy and immunogenicity of pneumococcal vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no trials comparing the efficacy of polysaccharide vaccine (PPSV-23) to conjugate vaccine in HIV-infected patients. Although there are no clinical data on the use of 13-valent conjugate vaccine (PCV-13), two prior clinical trials of the earlier 7-valent conjugate vaccine (PCV-7) demonstrated significant efficacy and immunogenicity with reduction of pneumococcal disease among HIV-infected adults in resource-limited settings. One of these trials also demonstrated a &ldquo;prime-boost effect&rdquo; of PCV-7 followed by PPSV-23 on inducing and maintaining protective immunity. (See",
"      <a class=\"local\" href=\"#H11160237\">",
"       'Efficacy and immunogenicity of pneumococcal vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend pneumococcal immunization in HIV-infected adults (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We prefer to administer the 13-valent conjugate vaccine based on efficacy and immunogenicity data with a related 7-valent conjugate vaccine among HIV-infected patients. The 13-valent conjugate vaccine has the advantage of covering additional pneumococcal serotypes that cause invasive disease. (See",
"      <a class=\"local\" href=\"#H273895\">",
"       'Vaccine recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dosing schedule of pneumococcal vaccine depends on the patient&rsquo;s immunization history. For patients who previously received one of more doses of polysaccharide vaccine, the 13-valent vaccine should be given one or more years later. Patients who have not been previously immunized against pneumococcal disease should receive a single dose of the 13-valent conjugate vaccine followed by a dose of polysaccharide vaccine at least eight weeks later (ie, a &ldquo;prime-boost&rdquo; strategy). (See",
"      <a class=\"local\" href=\"#H273914\">",
"       'Vaccine administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococcal immunization is more likely to be effective when administered when the patient&rsquo;s CD4 cell count is greater than 200",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and when HIV RNA suppression has been attained. (See",
"      <a class=\"local\" href=\"#H11160265\">",
"       'When to immunize'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initiation of antiretroviral therapy (ART) may play an important role in increasing the immunogenicity of pneumococcal vaccine and in improving innate immunity against encapsulated organisms. (See",
"      <a class=\"local\" href=\"#H11160265\">",
"       'When to immunize'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumocystis prophylaxis with agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      also decreases the risk of developing pneumococcal disease. (See",
"      <a class=\"local\" href=\"#H87043721\">",
"       'Role of prophylaxis against pneumocystis and pneumococcal disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/1\">",
"      Redd SC, Rutherford GW 3rd, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/2\">",
"      Pedersen RH, Lohse N, &Oslash;stergaard L, S&oslash;gaard OS. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med 2011; 12:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/3\">",
"      Jordano Q, Falc&oacute; V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/4\">",
"      Iwajomo OH, Finn A, Moons P, et al. Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV infection. J Infect Dis 2011; 204:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/5\">",
"      Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med 2005; 165:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/6\">",
"      Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007; 357:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/7\">",
"      Gilks CF, Ojoo SA, Ojoo JC, et al. Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/8\">",
"      Barry PM, Zetola N, Keruly JC, et al. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. AIDS 2006; 20:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/9\">",
"      Dworkin MS, Ward JW, Hanson DL, et al. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/10\">",
"      Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J Infect Dis 1996; 173:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/11\">",
"      French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/12\">",
"      Ho J, Moir S, Malaspina A, et al. Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc Natl Acad Sci U S A 2006; 103:19436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/13\">",
"      Teshale EH, Hanson D, Flannery B, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003. Vaccine 2008; 26:5830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/14\">",
"      Payeras A, Martinez P, Mil&agrave; J, et al. Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma) RIIa polymorphism characteristics. Clin Exp Immunol 2002; 130:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/15\">",
"      Pe&ntilde;aranda M, Falco V, Payeras A, et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 2007; 45:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/16\">",
"      Sogaard OS, Lohse N, Gerstoft J, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/17\">",
"      Guerrero M, Kruger S, Saitoh A, et al. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. AIDS 1999; 13:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/18\">",
"      Rosen JB, Thomas AR, Lexau CA, et al. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis 2011; 53:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/19\">",
"      Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012; 205:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/20\">",
"      Jain A, Jain S, Gant V. Should patients positive for HIV infection receive pneumococcal vaccine? BMJ 1995; 310:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/21\">",
"      French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/22\">",
"      Watera C, Nakiyingi J, Miiro G, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS 2004; 18:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/23\">",
"      Carson PJ, Schut RL, Simpson ML, et al. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis 1995; 172:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/24\">",
"      Janoff EN, Fasching C, Ojoo JC, et al. Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. J Infect Dis 1997; 175:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/25\">",
"      Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992; 165:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/26\">",
"      Loeliger AE, Rijkers GT, Aerts P, et al. Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients. FEMS Immunol Med Microbiol 1995; 12:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/27\">",
"      Weiss PJ, Wallace MR, Oldfield EC 3rd, et al. Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. J Infect Dis 1995; 171:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/28\">",
"      S&oslash;gaard OS, Sch&oslash;nheyder HC, Bukh AR, et al. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. AIDS 2010; 24:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/29\">",
"      Lesprit P, P&eacute;drono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/30\">",
"      S&oslash;gaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010; 51:42.",
"     </a>",
"    </li>",
"    <li>",
"     FDA expands use of Prevnar 13 vaccine for people ages 50 and older. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm285431.htm (Accessed on January 03, 2012).",
"    </li>",
"    <li>",
"     Prevnar 13 - Highlights of prescribing information. file://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201669.pdf (Accessed on January 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012; 61:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/34\">",
"      Hak E, Grobbee DE, Sanders EA, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378.",
"     </a>",
"    </li>",
"    <li>",
"     Medscape Internal Medicine. New ACIP recommendations on pneumococcal, influenza vaccines file://www.medscape.com/viewarticle/766113 (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/36\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11047/abstract/37\">",
"      Brichacek B, Swindells S, Janoff EN, et al. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996; 174:1191.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85526 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11047=[""].join("\n");
var outline_f10_50_11047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H274093\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272977\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11160230\">",
"      EPIDEMIOLOGY OF PNEUMOCOCCAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H273053\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H273655\">",
"      AVAILABLE VACCINE FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11160237\">",
"      EFFICACY AND IMMUNOGENICITY OF PNEUMOCOCCAL VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H273686\">",
"      Polysaccharide vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H273755\">",
"      Conjugate vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87043776\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H273895\">",
"      VACCINE RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H273914\">",
"      VACCINE ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11160265\">",
"      WHEN TO IMMUNIZE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87043721\">",
"      ROLE OF PROPHYLAXIS AGAINST PNEUMOCYSTIS AND PNEUMOCOCCAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274016\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274093\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=related_link\">",
"      Prevention of hepatitis B virus infection in the HIV-infected adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_50_11048="Cytokine synovial interactions";
var content_f10_50_11048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 653px\">",
"   <div class=\"ttl\">",
"    An overview of the cytokine-mediated regulation of synovial interactions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 633px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The component cells of the inflamed rheumatoid synovial membrane are depicted in innate and adaptive predominant compartments of the inflammatory response. Pivotal cytokine pathways are depicted in which activation of dendritic cells (DCs), T cells, B cells and macrophages underpins the dysregulated expression of cytokines that in turn drive activation of effector cells, including neutrophils, mast cells, endothelial cells and synovial fibroblasts. Bidirectional arrows represent a relationship between cells that is influenced by the cytokines listed.",
"    <div class=\"footnotes\">",
"     APRIL: a proliferation-inducing ligand; BAFF: B-cell activating factor; bFGF: basic fibroblast growth factor; CCL21: CC-chemokine ligand 21; CXCL13: CXC-chemokine ligand 13; FcgR: Fc receptor for IgG; IFN: interferon; IL: interleukin; LT&beta;: lymphotoxin-&beta;; M-CSF: macrophage colony-stimulating factor; PAR2: protease-activated receptor 2; RANKL: receptor activator of nuclear factor-&kappa;B (RANK) ligand; TGF&beta;: transforming growth factor-&beta;; T",
"     <sub>",
"      H",
"     </sub>",
"     : T helper; TLR: toll-like receptor; TNF: tumor-necrosis factor; VEGF: vascular endothelial growth factor.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers LTD: McInnes, IB, Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 6:429. Copyright &copy; 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11048=[""].join("\n");
var outline_f10_50_11048=null;
var title_f10_50_11049="Septic arthritis in adults";
var content_f10_50_11049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Septic arthritis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11049/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11049/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11049/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11049/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11049/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11049/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/50/11049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term septic arthritis usually refers to bacterial infection in a joint but also includes fungal and mycobacterial infections. Septic arthritis due to bacterial pathogens is often a dangerous and destructive form of acute arthritis. Predisposing factors, pathophysiology, clinical manifestations, diagnosis, and treatment of nongonococcal bacterial arthritis are reviewed here. Prosthetic joint infections, gonococcal arthritis, and fungal and mycobacterial arthritis are discussed separately because of their unique clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"     \"Disseminated gonococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link\">",
"     \"Skeletal tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of bacterial arthritis among adults presenting with one or a few acutely painful joints has been estimated to range from 8 to 27 percent, the lower figure arises from a consecutive series of 100 patients presenting to an urban hospital emergency department; the latter figure is based on a study of 75 patients presenting emergently in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These series included some patients with prosthetic joints and a small minority in whom the final diagnosis was gonococcal septic arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREDISPOSING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predisposing factors for septic arthritis in adults were identified in a 2007 systematic review that included a total of 6242 patients with acutely painful joints [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/3\">",
"     3",
"    </a>",
"    ]; 653 (10 percent) had septic arthritis. The predisposing factors and their predictive value (reflected by the estimated positive likelihood ratios [+LR]) are summarized as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age greater than 80 years",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Rheumatoid arthritis",
"     </li>",
"     <li>",
"      Prosthetic joint",
"     </li>",
"     <li>",
"      Recent joint surgery",
"     </li>",
"     <li>",
"      Skin infection, cutaneous ulcers",
"     </li>",
"     <li>",
"      IV drug abuse, alcoholism",
"     </li>",
"     <li>",
"      Previous intra-articular corticosteroid injection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these individual factors appears to have a modest impact on the risk of septic arthritis, however, combinations of independent risk factors substantially increase risk. As an example, acute joint pain in the presence of a joint prosthesis and concurrent evidence of skin infection is associated with a +LR of 15 (95% CI 8.1-28) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H21#H21\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Likelihood ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Source of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial arthritis can result from a bite or other trauma, from direct inoculation of bacteria during joint surgery, or rarely it can occur when pre-existing bony infection adjacent to a joint extends through the cortex into the joint space. However, in most cases, bacterial arthritis arises from hematogenous spread to the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. A retrospective review, for example, evaluated 191 cases of septic arthritis: 72 percent were thought to have arisen hematogenously [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/7\">",
"     7",
"    </a>",
"    ]. Common predisposing factors for hematogenous dissemination include injection drug use, indwelling catheters, and an underlying immunocompromised state such as HIV infection. Neonates and the elderly are at highest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, bacterial arthritis is the presenting sign of infective endocarditis (IE) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/9\">",
"     9",
"    </a>",
"    ]. This is most likely to occur in patients who use illicit injection drugs. Endocarditis should also be suspected when septic arthritis due to Staphylococcus aureus, enterococci, or streptococci occurs in a patient without an obvious predisposing cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hematogenously induced bacterial arthritis may present with joint abnormalities in the absence of signs of sepsis or bacteremia. These patients presumably acquired their infection from a transient or self-limiting bacteremia.",
"   </p>",
"   <p>",
"    It is unknown why only a small percentage of patients with bacteremia develop septic arthritis. For example, the incidence of pneumococcal septic arthritis in patients with pneumococcal bacteremia is extremely low (ranging from 0.5 to 0.7 percent in three different case series) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacterial arthritis can occur in conjunction with bacterial meningitis. A prospective cohort study of 696 episodes of community-acquired bacterial meningitis in adults evaluated the presence of arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/11\">",
"     11",
"    </a>",
"    ]. Arthritis was diagnosed in 48 or 696 (7 percent) of cases of meningitis. Joint fluid cultures were positive in 6 of 23 (26 percent) patients in whom aspiration was performed. Arthritis was most frequent in patients with meningococcal meningitis (12 percent).",
"   </p>",
"   <p>",
"    Bacterial arthritis can also occur by other mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sternoclavicular joint arthritis is a rare complication of subclavian vein catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Septic arthritis of the hip can rarely result from femoral venipuncture or ruptured colonic diverticular disease in which the infection dissects retroperitoneal into the posterior thigh and hip joint, presenting as a seemingly spontaneous-onset polymicrobial septic arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic arthritis does not appear to occur more often in patients with HIV infection than in other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/5\">",
"     5",
"    </a>",
"    ]. However, patients with advanced HIV infection may develop septic arthritis due to a variety of opportunistic organisms, including fungi or mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/15\">",
"     15",
"    </a>",
"    ], in addition to S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Underlying arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia is more likely to localize in a joint with preexisting arthritis, particularly if associated with synovitis. As an example, a prospective community-based study of 154 patients with bacterial arthritis found that 40 percent had preexisting joint disease, usually either rheumatoid arthritis or osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with rheumatoid arthritis (RA) appear to be especially prone to bacterial arthritis but the risk may also be increased in gout, pseudogout, osteoarthritis, and Charcot's arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Patients with RA may have additional predisposing factors, such as prior intraarticular steroid injections, maintenance immunosuppressive medications, and anti-tumor necrosis factor (TNF) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteria entering the joint initially deposit in the synovial membrane and produce an acute inflammatory cell response. Because synovial tissue has no limiting basement plate, bacterial organisms may quickly gain access to the synovial fluid, characteristically creating acute-onset, purulent joint inflammation. Following the onset of infection, there is marked hyperplasia of the lining cells in the synovial membrane within seven days. In addition, inflammatory cells release cytokines and proteases that cause cartilage degradation and inhibit cartilage synthesis. Pressure necrosis from large synovial effusions may result in further cartilage and bone loss.",
"   </p>",
"   <p>",
"    Bacterial DNA and bacterial toxins may have a deleterious effect on joint structures. As an example, extracts of unmethylated bacterial DNA from S. aureus or Escherichia coli produced arthritis in a murine model that lasted up to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/21\">",
"     21",
"    </a>",
"    ]. Bacterial superantigens, such as staphylococcal toxic shock syndrome toxin (TSST)-1 and staphylococcal enterotoxins may induce a potent inflammatory response that damages joint cartilage. Animals infected with strains of S. aureus expressing TSST-1 and enterotoxin, for example, developed severe arthritis, while those infected with strains in which these toxins were absent had no or only mild joint inflammation. Moreover, vaccination with recombinant forms of staphylococcal enterotoxin protected mice against severe arthritis due to enterotoxin containing staphylococci [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link&amp;anchor=H6#H6\">",
"     \"Staphylococcal toxic shock syndrome\", section on 'pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of surface components on organisms such as S. aureus may be important in the pathogenesis of septic arthritis. Adhesins, called \"microbial surface components recognizing adhesive matrix molecules\" (MSCRAMMs), mediate adherence of staphylococci to intraarticular proteins, such as fibronectin, laminin, elastin, collagen, hyaluronic acid, and to prosthetic joint materials. There is increasing experimental and clinical evidence that the presence or absence of genes encoding certain MSCRAMMs affects whether or not individual strains of S. aureus cause septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/23\">",
"     23",
"    </a>",
"    ]. A fibrinogen binding adhesion (FbsA) was a virulence factor in an animal model of septic arthritis following the intravenous injection of Streptococcus agalactiae [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/24\">",
"     24",
"    </a>",
"    ]. In contrast, the absence of pili-mediated adherence factors in organisms such as Kingella kingae seem to be paradoxically associated with a tendency to develop joint, bone, or endocardial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many pathogens are capable of causing bacterial arthritis (",
"    <a class=\"graphic graphic_table graphicRef57688 \" href=\"UTD.htm?36/22/37227\">",
"     table 1",
"    </a>",
"    ). S. aureus (including MRSA) is the most common bacterium infecting adult joints [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/4,6,26\">",
"     4,6,26",
"    </a>",
"    ]. Other gram-positive organisms such as streptococci are also frequent causes of septic arthritis. Septic arthritis due to gram-negative bacilli is generally observed in the setting of trauma, intravenous drug users, neonates, the elderly, and in association with underlying immunosuppression.",
"   </p>",
"   <p>",
"    Streptococcus pneumoniae cause a small but important percentage of cases of septic arthritis in adults. One review of 190 cases of pneumococcal septic arthritis noted that the majority of cases were monoarticular but that polyarticular involvement occurred in 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/10\">",
"     10",
"    </a>",
"    ]. Only one-half of the patients had another clinically apparent focus of pneumococcal infection.",
"   </p>",
"   <p>",
"    Septic arthritis is usually monomicrobial. Polymicrobial infections are less common and usually occur in the setting of penetrating trauma involving the joint space or via hematogenous seeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bacterial arthritis usually present acutely with a single swollen and painful joint (ie, monoarticular arthritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/27\">",
"     27",
"    </a>",
"    ]. The knee is involved in more than 50 percent of cases but wrists, ankles, and hips are commonly infected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/5\">",
"     5",
"    </a>",
"    ]. Infection of the symphysis pubis is uncommon but in a review of 100 cases four major underlying factors were identified including, patients who had undergone female incontinence surgery (24 percent), who were athletes (19 percent), who had pelvic malignancy (17 percent), or who used injection drugs (15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23876?source=see_link\">",
"     \"Pelvic osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 20 percent of septic joint infections are oligoarticular or polyarticular, usually involving two or three joints. Polyarticular septic arthritis is most likely to occur in patients with RA or other systemic connective tissue disease and in patients with overwhelming sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Joint pain, swelling, warmth, and restricted movement are self-reported by a majority of patients. These symptoms were noted at presentation in 85 and 78 percent, respectively, of patients with septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A majority of patients with bacterial arthritis are febrile, although chills and spiking fevers are unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinical experience suggests that elderly patients are more likely than others with septic arthritis to be afebrile. There may be evidence of an associated skin, urinary tract, or respiratory infection, which should provide a clue to the likely infecting organism (eg, S. aureus in patients presenting with skin and joint infections) (",
"    <a class=\"graphic graphic_table graphicRef57688 \" href=\"UTD.htm?36/22/37227\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Injection drug users have a predilection to develop bacterial arthritis in axial joints, such as the sternoclavicular [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/30\">",
"     30",
"    </a>",
"    ] or sternomanubrial joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial arthritis is part of the differential diagnosis of acute monoarthritis (",
"    <a class=\"graphic graphic_table graphicRef62597 \" href=\"UTD.htm?38/30/39404\">",
"     table 2",
"    </a>",
"    ). The definitive diagnostic test is identification of bacteria in the synovial fluid. Thus, at the initial suspicion of joint infection, synovial fluid aspiration should be performed; Gram stain, culture, and leukocyte count and differential of the aspirated fluid often leads to the correct diagnosis (",
"    <a class=\"graphic graphic_table graphicRef76506 \" href=\"UTD.htm?31/4/31820\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef53631 \" href=\"UTD.htm?9/54/10080\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of blood culture bottles for culture of synovial fluid has been recommended as a way to increase the rate of recovery of pathogens from patients with bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/31\">",
"     31",
"    </a>",
"    ]. However, a study of 94 synovial fluid cultures in 90 patients with acute joint effusions found no significant differences in the yield of positive cultures with the use of conventional agar plate culture, culture with lysis and centrifugation (Isolator) tubes, or broth enrichment blood culture bottles [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/32\">",
"     32",
"    </a>",
"    ]. In patients with clinical signs of septic arthritis, the joint fluid cultures were positive by all three methods in eight patients and negative by all three methods in 19 patients. The contamination rate was 1.5 percent in patients without clinical evidence of septic arthritis.",
"   </p>",
"   <p>",
"    If synovial fluid cannot be obtained with closed needle aspiration, the joint should be aspirated under computed tomography (CT) or fluoroscopic or ultrasound guidance. Certain joints, such as the hip or sacroiliac joint, may require surgical arthrotomy for diagnostic aspiration.",
"   </p>",
"   <p>",
"    The following results are typically obtained from synovial fluid analysis in patients with bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Synovial fluid culture is positive in the majority of patients with nongonococcal bacterial arthritis. Negative cultures may occur in those who have received recent antimicrobial therapy or are infected with a fastidious organism such as some streptococci or mycoplasma.",
"     </li>",
"     <li>",
"      Gram stain is positive in many but not all cases. The sensitivity is estimated to be from 29-50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/3\">",
"       3",
"      </a>",
"      ]. However, false positive results can be obtained because precipitated crystal violet and mucin in the synovial fluid can mimic gram-positive cocci. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The infected fluid is usually purulent with an average leukocyte count (most of which are neutrophils) of 50,000 to 150,000",
"      <span class=\"nowrap\">",
"       cells/mm3.",
"      </span>",
"      The likelihood of septic arthritis increases with rising synovial fluid leukocyte count [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The synovial fluid glucose is often depressed and lactic acid concentration is elevated; however, these tests are not sufficiently sensitive to be of widespread diagnostic utility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blood cultures are positive in approximately 50 percent of cases; thus, blood cultures should be obtained in any patient with suspected bacterial arthritis (even if fever is absent at the time of initial evaluation). Other laboratory findings, such as an increased white blood cell count and an elevated erythrocyte sedimentation rate, are common but nonspecific.",
"   </p>",
"   <p>",
"    Radiographs of the infected joint are usually normal at presentation but should be obtained in all patients since associated osteomyelitis or concurrent joint disease may rarely be present. In addition, a baseline radiograph is often useful for comparison purposes should the response to therapy be delayed or poor. Scintigraphy, CT scanning, or MR imaging can detect effusions and inflammation in joints that are difficult to examine, especially in the hip and sacroiliac joints [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are commonly measured in the early evaluation of patients with septic arthritis; these significance of the levels of these markers in uncertain. Elevations of CRP are usually present, though the sensitivity of the ESR test in patients with septic arthritis is inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of bacterial arthritis includes gout, pseudogout, reactive arthritis, RA, viral arthritis, and Lyme disease, each of which can present with acute involvement of one or a few joints (",
"    <a class=\"graphic graphic_table graphicRef62597 \" href=\"UTD.htm?38/30/39404\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Crystal-induced arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crystal-induced arthritis is very difficult to differentiate from bacterial arthritis on clinical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients with gout, for example, may have a monoarthritis with shaking chills, high fever, and leukocytosis. The diagnosis can be established by synovial fluid analysis, which should demonstrate the characteristic urate crystals of gout or the calcium pyrophosphate crystals of pseudogout. In addition, helpful clinical clues suggestive of gout include involvement of the first metatarsophalangeal joint, prior self-limited attacks of arthritis, and presence of tophi.",
"   </p>",
"   <p>",
"    Pseudogout may be more difficult to differentiate from a septic joint, since it often presents with acute knee or wrist synovitis. Radiographs demonstrating chondrocalcinosis are often helpful in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As some patients have concurrent crystal-induced and bacterial arthritis, we routinely culture and look for crystals in the synovial fluid from any joint with an acute effusion of unknown etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any form of chronic inflammatory joint disease can present with a new swollen joint that can simulate bacterial arthritis. This is especially common in the seronegative spondyloarthropathies, such as reactive arthritis. Most patients with reactive arthritis have recent genitourinary or gastrointestinal signs or symptoms, conjunctivitis, or skin or mucus membrane lesions. Occasionally patients with ankylosing spondylitis present with acute-onset hip arthritis that mimics septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rheumatoid arthritis (RA) is typically a symmetrical, chronic polyarthritis, an acute or subacute exacerbation of one or a few joints is common. It is important to differentiate such an exacerbation from concurrent bacterial arthritis. However, the correct diagnosis may be difficult to establish because the clinical findings may be somewhat atypical. As an example, many RA patients present indolently (rather than acutely) with bacterial arthritis, often with little fever or peripheral blood leukocytosis. Conversely, RA alone may present with a \"pseudoseptic arthritis\" picture, including an explosive acute synovitis with a marked synovial fluid leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, Gram stain and culture of synovial fluid are essential when evaluating the new onset of synovitis in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lyme disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lyme disease can present with an acute monoarthritis. The arthritis may develop weeks or months after the characteristic rash, fever, and migratory arthralgias. Patients are generally from, or have visited, an endemic area and seasonal exposure is historically helpful. At the time of arthritis, almost all patients should have IgG antibodies to Borrelia burgdorferi, which should be confirmed by a more specific method such as Western blot. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=see_link\">",
"     \"Diagnosis of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other arthritides should be included in the differential diagnosis of bacterial arthritis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycobacterial and fungal [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/39,40\">",
"       39,40",
"      </a>",
"      ] arthritis are much less common than bacterial arthritis, but have been seen more often in the context of HIV infection. An indolent monoarthritis is often the only symptom and synovial membrane histopathology and culture are frequently required to establish the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=see_link&amp;anchor=H8#H8\">",
"       \"Skeletal tuberculosis\", section on 'Arthritis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gonococcal arthritis can present with an acute monoarthritis, although migratory polyarthritis and tenosynovitis are more typical. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"       \"Disseminated gonococcal infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An acute traumatic arthritis usually causes bloody synovial fluid and is generally associated with a history of significant trauma to the joint.",
"     </li>",
"     <li>",
"      Mycoplasma spp can cause arthritis that mimics many of the features of other forms of septic arthritis, particularly in patients with hypogammaglobulinemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31177?source=see_link\">",
"       \"Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of acute bacterial arthritis requires appropriate antimicrobials and adequate joint drainage (",
"    <a class=\"graphic graphic_algorithm graphicRef77858 \" href=\"UTD.htm?22/55/23422\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled studies have evaluated antibiotic regimens for bacterial arthritis. The initial choice of antimicrobial regimens is based on coverage of the most likely organisms to cause infection in this setting, the Gram stain, the clinical presentation, and case series.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial Gram stain of the synovial fluid shows gram-positive cocci, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily IV in two divided doses, not to exceed 2 g per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the initial Gram stain of the synovial fluid shows gram-negative bacilli, we recommend therapy be initiated with a third generation cephalosporin. Suggested antibiotics and regimens include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      (1 to 2 g IV every eight hours) or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      (2 g IV once daily) or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      (2 g IV every eight hours)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      should be given with an aminoglycoside such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two or three divided doses) when Pseudomonas aeruginosa is considered to be a likely pathogen (eg, in patients who inject illicit drugs). In cephalosporin-allergic patients, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg IV every12 hours or 500 to 750 mg orally twice daily).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial Gram stain is negative, we treat with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      in the immunocompetent patient and with vancomycin plus a third generation cephalosporin in the immunocompromised patient, in injection drug users [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/42\">",
"       42",
"      </a>",
"      ] or in traumatic bacterial arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Modifications of the initial regimen can be made to narrow coverage when the culture and susceptibility results are available. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be discontinued in patients with staphylococcal or streptococcal infections that are susceptible to beta-lactam therapy. Septic arthritis due to MRSA should be treated with vancomycin; if this is not feasible due to allergy or drug intolerance, reasonable alternative agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    IV),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg PO or IV twice daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 mg PO or IV three times daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Intraarticular antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular antibiotics are not recommended as effective parenteral or oral therapy produce adequate levels of antimicrobial agents in joint fluid. Furthermore, direct instillation of antibiotics into a joint may cause an inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no controlled trials examining the duration of antimicrobial therapy in bacterial arthritis. Treatment recommendations are based on clinical case series and cannot be generalized for all patients. We typically give parenteral antibiotics for at least 14 days followed by oral therapy (if possible) for an additional 14 days. However, selected patients with infections due to organisms that are susceptible in vitro to oral agents with high bioavailability such as a fluoroquinolone can be successfully treated with a short course (four to seven days) of parenteral therapy followed by 14 to 21 days of oral therapy. Compliance and response to therapy should be monitored carefully in all such patients.",
"   </p>",
"   <p>",
"    Longer courses of parenteral antimicrobial therapy (eg, three to four weeks) may be necessary to cure selected patients with difficult to treat pathogens such as P. aeruginosa or Enterobacter spp. Furthermore, we routinely advise a four week course of therapy in patients who have documented bacteremia and secondary S. aureus arthritis; a shorter duration of therapy in such patients is likely to result in relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Joint drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled studies have evaluated joint drainage procedures in adults for bacterial arthritis. Thus, recommendations are based on small retrospective studies and are dependent on the joint affected and the time from onset of infection until evaluation.",
"   </p>",
"   <p>",
"    Although no studies have compared drainage to no drainage procedure, we recommend joint drainage in all patients with septic arthritis as this condition represents a closed abscess collection. The three procedures used are needle aspiration (single or multiple), arthroscopic drainage, or arthrotomy (open surgical drainage). Most peripheral joints can be drained with closed needle aspiration; daily aspiration may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/43\">",
"     43",
"    </a>",
"    ]. If adequate drainage cannot be obtained by needle aspiration, either arthroscopy or open drainage is necessary.",
"   </p>",
"   <p>",
"    Adequacy of needle aspiration is best assessed using clinical criteria, including improvement in temperature, white cell count, joint swelling and pain. Improvement in joint swelling is easier to assess in the knee than in the hip or shoulder. In most cases, initial surgical drainage is warranted for hips, shoulders, or prosthetic joint infections. Surgical drainage should also be undertaken for any joint that is not improving clinically after serial needle aspiration or if needle drainage is inadequate to remove the fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For knee, shoulder, and wrist infections, arthroscopy is often preferred because of easier irrigation and better visualization of the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. A multicenter study of 46 cases of septic arthritis of the knee treated by arthroscopic drainage showed a bacteriologic cure rate of 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/44\">",
"     44",
"    </a>",
"    ]. A retrospective study of 76 patients with septic arthritis (62 knee, 10 shoulder, five ankle joints, and one hip joint) evaluated initial arthroscopic management [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/45\">",
"     45",
"    </a>",
"    ]. Outcomes were dependent on the stage of infection, with more severe infections more likely to require repeated arthroscopic irrigations.",
"   </p>",
"   <p>",
"    For hip infections, initial open surgical drainage may be necessary. Although arthrotomy has been considered standard treatment, a retrospective study involving six patients with septic hips found that arthroscopic treatment with large-volume irrigation was effective [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/47\">",
"     47",
"    </a>",
"    ]. Further clinical studies will be needed to determine the best approach.",
"   </p>",
"   <p>",
"    After initial treatment, serial synovial fluid analyses should demonstrate that the fluid has become sterile and that the total leukocyte count is decreasing. If not, more definitive joint drainage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an alteration in the antimicrobial regimen should be considered. Infected knees often continue to accumulate synovial fluid and require daily aspiration for 7 to 10 days. Attention should also be paid to joint position and rapid mobilization to prevent contractures and promote optimal nutrition to the articular cartilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of bacterial arthritis has",
"    <strong>",
"     not",
"    </strong>",
"    improved significantly in the past few decades, despite better antibiotics and drainage. It is extremely difficult to predict the functional outcome of individual patients during and at the conclusion of treatment. The outcome is directly related to host factors, such as prior joint damage, the virulence of the infecting organism, and the speed with which adequate treatment is begun.",
"   </p>",
"   <p>",
"    As an example, a study evaluated 121 adults and 31 children with bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/16\">",
"     16",
"    </a>",
"    ]. A poor joint outcome (as defined by the need for amputation, arthrodesis, prosthetic surgery or severe functional deterioration) occurred in one-third of the patients. Adverse prognostic factors included older age, preexisting joint disease, and an infected joint containing synthetic material.",
"   </p>",
"   <p>",
"    In addition, inflammation and destruction of joints may continue even in those with sterile joints despite effective antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/48\">",
"     48",
"    </a>",
"    ]. This may be due to the persistence of bacterial DNA within the joint, which has been shown to induce arthritis in an animal model of septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogen may also have an important influence on the outcome of treatment. In the series of patients with pneumococcal bacterial arthritis, for example, 95 percent of adults and 90 percent of children had a return to baseline joint function or only mild limitation of joint motion following the completion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/10\">",
"     10",
"    </a>",
"    ]. These results are in contrast to other studies of S. aureus bacterial arthritis that report 46 to 50 percent with poor joint outcomes following therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/6,49\">",
"     6,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality due to bacterial arthritis is dependent upon the presence of co-morbid conditions such as advanced age, coexistent renal or cardiac disease, and immunosuppression. The mortality rates in most series have ranged from 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/16\">",
"     16",
"    </a>",
"    ]. Polyarticular septic arthritis, particularly when it is due to S. aureus or occurs in the presence of rheumatoid arthritis, has an extremely poor prognosis with mortality rates as high as 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/29\">",
"     29",
"    </a>",
"    ]. Mortality due to septic pneumococcal arthritis was reported as 19 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11049/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/63/17393?source=see_link\">",
"       \"Patient information: Septic arthritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/10/30881?source=see_link\">",
"       \"Patient information: Arthritis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=see_link\">",
"       \"Patient information: Joint infection (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nongonococcal bacterial arthritis is frequently a dangerous and destructive form of acute arthritis. Bacterial arthritis can result from a bite or other trauma, from direct inoculation of bacteria during joint surgery, or rarely, when infection of bone adjacent to the joint extends through the cortex into the joint space. However, in most cases, bacterial arthritis arises from hematogenous spread to the joint. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Predisposing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacteremia is more likely to localize in a joint with preexisting arthritis, particularly if associated with synovitis. Thus, patients with rheumatoid arthritis (RA) appear to be especially prone to bacterial arthritis but the risk is also increased in gout, pseudogout, osteoarthritis, and Charcot's arthropathy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Underlying arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virtually any microbial pathogen is capable of causing bacterial arthritis. However, organisms such as S. aureus and streptococci have a higher propensity to cause joint infections than gram-negative bacilli, which typically only produce these infections after trauma or in patients with severe underlying immunosuppression. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with bacterial (nongonococcal) arthritis present acutely with a single swollen and painful joint (ie, monoarticular arthritis). The knee is involved in more than 50 percent of cases but wrists, ankles, and hips are commonly infected. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial arthritis is part of the differential diagnosis of acute monoarthritis (",
"      <a class=\"graphic graphic_table graphicRef62597 \" href=\"UTD.htm?38/30/39404\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definitive diagnostic test is identification of bacteria in the synovial fluid. Thus, at the initial suspicion of joint infection, synovial fluid aspiration should be performed; Gram stain, culture, and leukocyte count and differential of the aspirated fluid often leads to the correct diagnosis (",
"      <a class=\"graphic graphic_table graphicRef76506 \" href=\"UTD.htm?31/4/31820\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef53631 \" href=\"UTD.htm?9/54/10080\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that the initial choice of antibiotics for treatment of acute nontraumatic bacterial arthritis be based on the Gram stain (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that if the bacterial arthritis is due to trauma, or if the Gram stain is negative, the initial choice of antibiotics for treatment be based on coverage of the most likely organisms to cause infection in the clinical setting (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Typical antibiotic regimens include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the initial Gram stain of the synovial fluid shows gram-positive cocci, we treat with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily IV in two divided doses).",
"     </li>",
"     <li>",
"      If the initial Gram stain of the synovial fluid shows gram-negative bacilli, we treat with a third generation cephalosporin, such as:",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      (1 to 2 g IV every eight hours)",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g IV once daily)",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (2 g IV every eight hours).",
"     </li>",
"     <li>",
"      When Pseudomonas aeruginosa is considered to be a likely pathogen (eg, in patients who inject illicit drugs), we treat with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      and an aminoglycoside such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two or three divided doses).",
"     </li>",
"     <li>",
"      In cephalosporin-allergic patients, we treat with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg IV every12 hours or 500 to 750 mg orally twice daily).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial Gram stain is negative, we treat with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      in the immunocompetent patient and with vancomycin plus a third generation cephalosporin in the immunocompromised patient or in traumatic bacterial arthritis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modifications of the initial antibiotic regimen should be made to narrow coverage when the culture and susceptibility results are available. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical duration of therapy is three to four weeks combined intravenous (approximately two weeks) and oral. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend joint drainage be performed in all patients with bacterial arthritis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_algorithm graphicRef77858 \" href=\"UTD.htm?22/55/23422\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Joint drainage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/1\">",
"      Shmerling RH, Delbanco TL, Tosteson AN, Trentham DE. Synovial fluid tests. What should be ordered? JAMA 1990; 264:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/2\">",
"      Jeng GW, Wang CR, Liu ST, et al. Measurement of synovial tumor necrosis factor-alpha in diagnosing emergency patients with bacterial arthritis. Am J Emerg Med 1997; 15:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/3\">",
"      Margaretten ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA 2007; 297:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/4\">",
"      Mathews CJ, Coakley G. Septic arthritis: current diagnostic and therapeutic algorithm. Curr Opin Rheumatol 2008; 20:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/5\">",
"      Goldenberg DL. Septic arthritis and other infections of rheumatologic significance. Rheum Dis Clin North Am 1991; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/6\">",
"      Goldenberg DL, Reed JI. Bacterial arthritis. N Engl J Med 1985; 312:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/7\">",
"      Morgan DS, Fisher D, Merianos A, Currie BJ. An 18 year clinical review of septic arthritis from tropical Australia. Epidemiol Infect 1996; 117:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/8\">",
"      Gavet F, Tournadre A, Soubrier M, et al. Septic arthritis in patients aged 80 and older: a comparison with younger adults. J Am Geriatr Soc 2005; 53:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/9\">",
"      Sapico FL, Liquete JA, Sarma RJ. Bone and joint infections in patients with infective endocarditis: review of a 4-year experience. Clin Infect Dis 1996; 22:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/10\">",
"      Ross JJ, Saltzman CL, Carling P, Shapiro DS. Pneumococcal septic arthritis: review of 190 cases. Clin Infect Dis 2003; 36:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/11\">",
"      Weisfelt M, van de Beek D, Spanjaard L, de Gans J. Arthritis in adults with community-acquired bacterial meningitis: a prospective cohort study. BMC Infect Dis 2006; 6:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/12\">",
"      Aglas F, Gretler J, Rainer F, Krejs GJ. Sternoclavicular septic arthritis: a rare but serious complication of subclavian venous catheterization. Clin Rheumatol 1994; 13:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/13\">",
"      Fromm SE, Toohey JS. Septic arthritis of the hip in an adult following repeated femoral venipuncture. Orthopedics 1996; 19:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/14\">",
"      Messieh M, Turner R, Bunch F, Camer S. Hip sepsis from retroperitoneal rupture of diverticular disease. Orthop Rev 1993; 22:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/15\">",
"      Reveille JD. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum 2000; 30:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/16\">",
"      Kaandorp CJ, Krijnen P, Moens HJ, et al. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum 1997; 40:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/17\">",
"      Mor A, Mitnick HJ, Greene JB, et al. Relapsing oligoarticular septic arthritis during etanercept treatment of rheumatoid arthritis. J Clin Rheumatol 2006; 12:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/18\">",
"      Nadarajah K, Pritchard C. Listeria monocytogenes septic arthritis in a patient treated with etanercept for rheumatoid arthritis. J Clin Rheumatol 2005; 11:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/19\">",
"      Schett G, Herak P, Graninger W, et al. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol 2005; 43:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/20\">",
"      Katsarolis I, Tsiodras S, Panagopoulos P, et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005; 37:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/21\">",
"      Deng GM, Tarkowski A. The features of arthritis induced by CpG motifs in bacterial DNA. Arthritis Rheum 2000; 43:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/22\">",
"      Nilsson IM, Verdrengh M, Ulrich RG, et al. Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity. J Infect Dis 1999; 180:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/23\">",
"      Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev 2002; 15:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/24\">",
"      Jonsson IM, Pietrocola G, Speziale P, et al. Role of fibrinogen-binding adhesin expression in septic arthritis and septicemia caused by Streptococcus agalactiae. J Infect Dis 2005; 192:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/25\">",
"      Kehl-Fie TE, Porsch EA, Yagupsky P, et al. Examination of type IV pilus expression and pilus-associated phenotypes in Kingella kingae clinical isolates. Infect Immun 2010; 78:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/26\">",
"      Frazee BW, Fee C, Lambert L. How common is MRSA in adult septic arthritis? Ann Emerg Med 2009; 54:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/27\">",
"      Mikhail IS, Alarc&oacute;n GS. Nongonococcal bacterial arthritis. Rheum Dis Clin North Am 1993; 19:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/28\">",
"      Ross JJ, Hu LT. Septic arthritis of the pubic symphysis: review of 100 cases. Medicine (Baltimore) 2003; 82:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/29\">",
"      Dubost JJ, Fis I, Denis P, et al. Polyarticular septic arthritis. Medicine (Baltimore) 1993; 72:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/30\">",
"      Ross JJ, Shamsuddin H. Sternoclavicular septic arthritis: review of 180 cases. Medicine (Baltimore) 2004; 83:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/31\">",
"      von Essen R, H&ouml;ltt&auml; A. Improved method of isolating bacteria from joint fluids by the use of blood culture bottles. Ann Rheum Dis 1986; 45:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/32\">",
"      Kortekangas P, Aro HT, Lehtonen OP. Synovial fluid culture and blood culture in acute arthritis. A multi-case report of 90 patients. Scand J Rheumatol 1995; 24:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/33\">",
"      Zimmermann B 3rd, Mikolich DJ, Lally EV. Septic sacroiliitis. Semin Arthritis Rheum 1996; 26:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/34\">",
"      Ernst AA, Weiss SJ, Tracy LA, Weiss NR. Usefulness of CRP and ESR in predicting septic joints. South Med J 2010; 103:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/35\">",
"      Hariharan P, Kabrhel C. Sensitivity of erythrocyte sedimentation rate and C-reactive protein for the exclusion of septic arthritis in emergency department patients. J Emerg Med 2011; 40:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/36\">",
"      Baker DG, Schumacher HR Jr. Acute monoarthritis. N Engl J Med 1993; 329:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/37\">",
"      Mathur T, Manadan AM, Hota B, Block JA. Pseudo-septic hip arthritis as the presenting symptom of ankylosing spondylitis: a case series and review of the literature. Clin Exp Rheumatol 2010; 28:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/38\">",
"      Singleton JD, West SG, Nordstrom DM. \"Pseudoseptic\" arthritis complicating rheumatoid arthritis: a report of six cases. J Rheumatol 1991; 18:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/39\">",
"      Yang SC, Shao PL, Hsueh PR, et al. Successful treatment of Candida tropicalis arthritis, osteomyelitis and costochondritis with caspofungin and fluconazole in a recipient of bone marrow transplantation. Acta Paediatr 2006; 95:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/40\">",
"      Dalton PA, Munckhof WJ, Walters DW. Scedosporium prolificans: an uncommon cause of septic arthritis. ANZ J Surg 2006; 76:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/41\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/42\">",
"      Allison DC, Holtom PD, Patzakis MJ, Zalavras CG. Microbiology of bone and joint infections in injecting drug abusers. Clin Orthop Relat Res 2010; 468:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/43\">",
"      Ho G Jr. How best to drain an infected joint. Will we ever know for certain? J Rheumatol 1993; 20:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/44\">",
"      Thiery JA. Arthroscopic drainage in septic arthritides of the knee: a multicenter study. Arthroscopy 1989; 5:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/45\">",
"      Stutz G, Kuster MS, Kleinst&uuml;ck F, G&auml;chter A. Arthroscopic management of septic arthritis: stages of infection and results. Knee Surg Sports Traumatol Arthrosc 2000; 8:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/46\">",
"      Sammer DM, Shin AY. Comparison of arthroscopic and open treatment of septic arthritis of the wrist. J Bone Joint Surg Am 2009; 91:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/47\">",
"      Nusem I, Jabur MK, Playford EG. Arthroscopic treatment of septic arthritis of the hip. Arthroscopy 2006; 22:902.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/48\">",
"      Goldenberg DL. Septic arthritis. Lancet 1998; 351:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11049/abstract/49\">",
"      Weston VC, Jones AC, Bradbury N, et al. Clinical features and outcome of septic arthritis in a single UK Health District 1982-1991. Ann Rheum Dis 1999; 58:214.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7666 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C815FD8784-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11049=[""].join("\n");
var outline_f10_50_11049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREDISPOSING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Source of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Underlying arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Microbiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Crystal-induced arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Intraarticular antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Joint drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7666|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/54/10080\" title=\"algorithm 1\">",
"      Dx bacterial arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/55/23422\" title=\"algorithm 2\">",
"      Rx bacterial arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7666|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/22/37227\" title=\"table 1\">",
"      Etiology infectious arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/30/39404\" title=\"table 2\">",
"      Differential monoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/4/31820\" title=\"table 3\">",
"      Categories of synovial fluid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28425?source=related_link\">",
"      Diagnosis of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31177?source=related_link\">",
"      Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/10/30881?source=related_link\">",
"      Patient information: Arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/21/18769?source=related_link\">",
"      Patient information: Joint infection (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/63/17393?source=related_link\">",
"      Patient information: Septic arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23876?source=related_link\">",
"      Pelvic osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_50_11050="Cardioversion for specific arrhythmias";
var content_f10_50_11050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardioversion for specific arrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11050/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11050/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11050/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11050/contributors\">",
"     Richard L Page, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/50/11050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/50/11050/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/50/11050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical cardioversion and defibrillation have become routine procedures in the management of patients with cardiac arrhythmias. Cardioversion is the delivery of energy that is synchronized to the QRS complex, while defibrillation is nonsynchronized delivery of a shock randomly during the cardiac cycle.",
"   </p>",
"   <p>",
"    Early defibrillators delivered energy in a monophasic waveform, meaning that electrons flowed in a single direction. The newer defibrillators deliver a biphasic waveform, meaning that during the shock, polarity and electron flow reverse. In addition to reversing polarity, biphasic defibrillators also deliver a more consistent magnitude of current (",
"    <a class=\"graphic graphic_figure graphicRef51842 \" href=\"UTD.htm?23/36/24140\">",
"     figure 1",
"    </a>",
"    ). In general, biphasic defibrillators successfully terminate arrhythmias at lower energies than monophasic defibrillators. The relative efficacy of biphasic and monophasic defibrillators has been compared in a number of settings and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H11#H11\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Monophasic versus biphasic waveforms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the clinical settings in which electrical cardioversion and defibrillation are used, along with a brief discussion of the complications that can occur independent of the arrhythmia that is being treated. The basic principles and technique of electrical cardioversion and defibrillation, the specific indications for external cardioversion and defibrillation, and the use of the automated external defibrillator are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link\">",
"     \"Automated external defibrillators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EXTERNAL CARDIOVERSION/DEFIBRILLATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2562597\">",
"    <span class=\"h2\">",
"     Energy selection for defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of energy selected for initial attempts of defibrillation has been controversial. The energy selected should be sufficient to accomplish prompt defibrillation because repeated failures expose the heart to damage from prolonged ischemia and multiple shocks. On the other hand, excessive energy should be avoided, since myocardial damage from high-energy shocks has been demonstrated in experimental studies, although the frequency with which this occurs in humans is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006 the American College of Cardiology, American Heart Association, and the European Society of Cardiology issued separate guidelines for the management of patients with atrial fibrillation and the management of patients with ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In 2010, the American Heart Association issued guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/5\">",
"     5",
"    </a>",
"    ]. We agree with the suggested initial energy selection for specific arrhythmias as addressed in each of the society guidelines. The following are suggested initial energy requirements for monophasic and biphasic waveforms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For atrial fibrillation, 120 to 200 joules for biphasic devices and 200 joules for monophasic devices (",
"      <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For atrial flutter, 50 to 100 joules for biphasic devices and 100 joules for monophasic devices.",
"     </li>",
"     <li>",
"      For ventricular tachycardia with a pulse, 100 joules for biphasic devices and 200 joules for monophasic devices.",
"     </li>",
"     <li>",
"      For ventricular fibrillation or pulseless ventricular tachycardia, 120 to 200 joules for biphasic devices and 360 joules for monophasic devices (",
"      <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"       algorithm 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardioversion with higher energy levels may be effective when prior cardioversion attempts using a maximal energy of 360 joules have failed to restore sinus rhythm. In one study, 55 patients who did not have sinus rhythm restored after at least two attempts of external cardioversion with 360 joules underwent cardioversion with 720 joules, which was performed by using two external cardioverters, each connected to its own pair of patches [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/6\">",
"     6",
"    </a>",
"    ]. Sinus rhythm was restored in 84 percent of these patients with no major complications, hemodynamic compromise, or strokes occurring after the procedure.",
"   </p>",
"   <p>",
"    As another option besides high-energy cardioversion, pretreatment with an antiarrhythmic drug can facilitate cardioversion at lower energy levels. Pretreatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    prior to electrical cardioversion has been shown to significantly improve the rate of successful cardioversion to sinus rhythm and was also associated with the use of significantly lower energy levels to achieve cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    have also been shown to increase the likelihood of successful cardioversion or lower the energy threshold required for cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/8\">",
"     8",
"    </a>",
"    ]. When an antiarrhythmic drug is chosen, however, the potential side effects must be carefully considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1682749\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;External cardioversion and defibrillation have been used in the treatment of a variety of arrhythmias, with variable results depending on the chronicity of the arrhythmia, triggers for the arrhythmia, and the patient&rsquo;s overall clinical condition. For example, electrical cardioversion success rates approach 100 percent in patients with atrial flutter or atrial fibrillation of short duration and no structural heart disease, while the success rates are much lower in patients with chronic atrial fibrillation and concomitant mitral valve disease.",
"   </p>",
"   <p>",
"    While antiarrhythmic medications can sometimes result in restoration of sinus rhythm without electrical cardioversion, they are primarily used in an effort to maintain sinus rhythm following successful electrical cardioversion. However, many antiarrhythmic drugs can alter the defibrillation threshold, ie, the minimal amount of energy necessary for reversion of an arrhythmia (",
"    <a class=\"graphic graphic_table graphicRef81781 \" href=\"UTD.htm?6/9/6299\">",
"     table 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    may cause a significant rise in defibrillation thresholds [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is the most frequent arrhythmia treated with electrical cardioversion. Cardioversion is part of the overall treatment approach to AF, which also includes rate control and anticoagulation. To reduce the risk of thromboembolism following cardioversion, anticoagulation is generally recommended for three to four weeks before and after cardioversion. Alternatively, the presence of existing intracardiac thrombus should be excluded using transesophageal echocardiography prior to cardioversion if therapeutic anticoagulation has not been achieved. Detailed discussions regarding the decision to perform cardioversion versus rate control, as well as the optimal approach to anticoagulation, are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=see_link&amp;anchor=H6#H6\">",
"     \"Role of echocardiography in atrial fibrillation\", section on 'Transesophageal echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The energy requirement for successful cardioversion of AF varies according to the type of electrical waveform and chronicity of AF (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H18#H18\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Energy selection for defibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When monophasic waveforms are used, 100 to 200 joules (watt-seconds) is often adequate to restore sinus rhythm, although &gt;200 joules may be required, particularly for AF of long duration. The overall success rate (at any level of energy) of electrical cardioversion for AF is 75 to 95 percent and is related inversely both to the duration of AF and to left atrial size [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When biphasic waveforms are used, the energy requirements are less (generally 50 percent of that required with monophasic waveforms) and efficacy is higher [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. In a study of 912 patients with AF or atrial flutter, restoration of sinus rhythm was higher with the use of biphasic waveforms (94 versus 84 percent for monophasic waveforms) and the cumulative energy was lower (199 J versus 554 J) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/15\">",
"       15",
"      </a>",
"      ]. The use of biphasic waveforms may be of particular benefit in patients who fail to revert with the use of monophasic waveforms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it had been hoped that cardioversion to and maintenance of sinus rhythm would improve the prognosis of and reduce embolic risk in patients with AF, this concept was not confirmed in the two largest randomized trials comparing rate control plus anticoagulation versus rhythm control for AF (the AFFIRM and RACE trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Both studies showed a trend toward a lower incidence of the primary endpoint with rate control and anticoagulation (hazard ratio 0.87 for mortality in AFFIRM and 0.73 for a composite endpoint in RACE). In addition, embolization occurred with equal frequency regardless of whether a rhythm control or a rate control strategy was adopted. In both groups, embolization primarily occurred after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    had been stopped or when the INR was subtherapeutic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical cardioversion is highly successful in the treatment of typical (type I) atrial flutter, which arises from a single reentrant circuit in the right atrium (",
"    <a class=\"graphic graphic_waveform graphicRef75931 \" href=\"UTD.htm?32/7/32884\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52904 \" href=\"UTD.htm?27/10/27811\">",
"     figure 2",
"    </a>",
"    ). The energy requirement for successful cardioversion of typical (type I) atrial flutter is usually lower than that required for atrial fibrillation (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/5\">",
"     5",
"    </a>",
"    ]. Many patients with type I atrial flutter can be cardioverted with 50 to 100 joules or less, particularly with biphasic defibrillators [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/3,20-22\">",
"     3,20-22",
"    </a>",
"    ]. In a review including 985 cardioversions in 840 patients with atrial flutter, the median energy level for successful cardioversion was 50 joules with a biphasic defibrillatory and 200 joules with a monophasic defibrillator [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H18#H18\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Energy selection for defibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to typical (type I) atrial flutter, atypical (type II) atrial flutter may result from reentrant circuits in various locations and tends to require higher energy levels for cardioversion, but in most cases sinus rhythm can be successfully restored. While starting at 50 to 100 joules may be effective for cardioversion of atypical (type II) atrial flutter, particularly with biphasic defibrillators, this approach has the potential adverse effect of requiring additional shocks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of anticoagulation during and after cardioversion is similar to that with atrial fibrillation and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=see_link\">",
"     \"Embolic risk and the role of anticoagulation in atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common mechanisms for supraventricular tachycardia are atrioventricular (AV) nodal reentry and AV reentrant tachycardia. These arrhythmias often terminate with vagal maneuvers or intravenous antiarrhythmic therapy with adenosine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ; as such, electrical cardioversion is usually not required. However, if these arrhythmias persist and electrical cardioversion is attempted, cardioversion is usually successful but may require relatively high energy levels, probably due to the deep location of the reentrant pathway. If sinus rhythm is not restored following an initial 50 to 100 joule shock, subsequent shocks should be at higher energy levels (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 1",
"    </a>",
"    ). Although energy requirements with biphasic waveforms have not been reported, they are likely to be lower than for monophasic waveforms based upon experience with other arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical cardioversion is usually successful in the acute treatment of ventricular tachycardia (VT), which typically arises from a reentrant circuit in the ventricle. If a distinct QRS and T wave are identified, allowing the delivery of energy to be synchronized to the QRS complex, monomorphic VT can often be terminated with a low-energy shock. Despite the potential for terminating VT with very low-energy shocks, one must consider the seriousness of the arrhythmia and the desire to avoid repeated shocks. As a result, the initial synchronized shock in these circumstances is recommended to be 100 joules with a biphasic waveform and 200 joules with a monophasic waveform (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H18#H18\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Energy selection for defibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, synchronized cardioversion may be impossible or hazardous if the VT is rapid and distinct QRS complexes are not identified, if the QRS complexes are wide and bizarre, or if the VT is polymorphic. In these settings, there is a potential for delivery of a discharge on the T wave, possibly provoking ventricular fibrillation. Under these circumstances, nonsynchronized defibrillation should be performed starting with 120 to 200 joules for a biphasic device or 360 joules for a monophasic device. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Ventricular fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only definitive treatment for ventricular fibrillation (VF) is defibrillation. When defibrillation is performed promptly, the success rate for terminating ventricular fibrillation can be as high as 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. However, the success rate falls substantially as the duration of ventricular fibrillation increases, probably due to myocardial ischemia, acidosis, and other metabolic changes. These cellular changes are associated with an electrophysiologic deterioration of ventricular fibrillation, leading to an increase in fibrillation cycle length and prolonged diastolic duration between fibrillation action potentials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, defibrillation as soon as possible has been considered to be the standard of care for VF (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"     algorithm 2",
"    </a>",
"    ). Some studies suggest that when VF has been present for longer than four to five minutes, outcomes are better if cardiopulmonary resuscitation is performed prior to defibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The recommended starting energy to effectively defibrillate VF is 360 joules when monophasic waveforms are used and 120 to 200 joules with biphasic waveforms (",
"    <a class=\"graphic graphic_algorithm graphicRef62714 \" href=\"UTD.htm?20/21/20819\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/5\">",
"     5",
"    </a>",
"    ]. There is no reported benefit to using more than 360 joules, and there may be harm since high-energy shocks may be associated with myocardial damage and the risk for developing new arrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link&amp;anchor=H3#H3\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\", section on 'Defibrillation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H8#H8\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Ventricular fibrillation and pulseless ventricular tachycardia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H18#H18\">",
"     \"Basic principles and technique of cardioversion and defibrillation\", section on 'Energy selection for defibrillation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2560757\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3424080\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cardioversion during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion can be performed during pregnancy without affecting the rhythm of the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. It is recommended, however, that the fetal heart rate be monitored during the procedure using standard fetal monitoring techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link\">",
"     \"Antepartum fetal heart rate assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Cardioversion in patients with permanent pacemakers/ICDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several precautions are necessary when attempting external electrical cardioversion or defibrillation in a patient with a permanent pacemaker or an implantable cardioverter defibrillator (ICD). Defibrillation in these patients can damage the pulse generator, the lead system, or the myocardial tissue, resulting in device dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/32\">",
"     32",
"    </a>",
"    ]. The electrode paddle (or patch) should be at least 12 cm from the pulse generator and an anteroposterior paddle position is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Elective cardioversion should be initiated with the lowest indicated energy (which will vary depending on the arrhythmia) in order to avoid damage to the device circuitry and the electrode-myocardial interface. After cardioversion, the pacemaker should be interrogated and evaluated to ensure normal pacemaker function. When these precautions have been used, cardioversion with either monophasic or biphasic shocks is safe and effective in patients with an implantable device [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, in patients with an ICD, internal cardioversion can be attempted by a cardiologist using the device programmer to deliver the shock. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Internal cardioversion/defibrillation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2561692\">",
"    <span class=\"h3\">",
"     Cardioversion in patients with digitalis toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with digitalis overdose or intoxication can present with almost any type of arrhythmia, including tachyarrhythmias and bradyarrhythmias. In particular, ventricular arrhythmias (including VF) are more likely to occur in patients who have digitalis toxicity, especially if the patient is also hypokalemic. There is a relative contraindication to cardioversion in the setting of digitalis toxicity since digitalis sensitizes the heart to the electrical stimulus and, hence, cardioversion could trigger additional arrhythmias, most importantly ventricular fibrillation. However, if cardioversion must be performed for a life-threatening ventricular arrhythmia, prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    up to a maximum dose of 100 mg IV push) should be given and the lowest indicated energy levels used. Hypokalemia should be corrected prior to cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"     \"Digitalis (cardiac glycoside) poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560757\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;While electrical cardioversion and defibrillation are generally well tolerated, complications may occur. Most complications are self-limiting (eg, changes in the electrocardiogram, hypotension related to sedation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasodilation) or relatively benign (eg, skin irritation). However, providers should be aware of potential life-threatening complications such as postcardioversion arrhythmias and the possibility of thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560837\">",
"    <span class=\"h3\">",
"     ST segment and T wave changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic (ECG) changes can occur immediately after cardioversion, usually consisting of ST segment and T wave changes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. ECG changes, including ST segment elevation, are nonspecific findings and should not be used as the sole criteria for identifying an acute ischemic event as the cause for the ventricular tachyarrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 56 patients with ventricular arrhythmias treated with monophasic shocks, ST segment and T wave changes were common immediately after cardioversion but usually resolved within five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/36\">",
"     36",
"    </a>",
"    ]. The ECG changes included ST segment elevation in 15 percent, ST segment depression in 35 percent, or an increase in T wave amplitude.",
"   </p>",
"   <p>",
"    Transient ST elevation has also been reported in a series of patients undergoing cardioversion with monophasic waveforms for atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/37\">",
"     37",
"    </a>",
"    ]. These changes were noted primarily in the precordial leads, and normalized within 1.5 minutes. The occurrence of ST segment elevation was associated with a lower conversion rate and lower rate of long-term maintenance of sinus rhythm.",
"   </p>",
"   <p>",
"    The pathogenesis of ST elevation is uncertain, since elevations in cardiac enzymes (ie, CK-MB and troponin) are uncommon and, when they occur, are usually minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. However, both the incidence and the extent of ST segment changes appears to be lower with the use of biphasic waveforms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560844\">",
"    <span class=\"h3\">",
"     Arrhythmia and conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias are frequently observed after cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/13,36,46-48\">",
"     13,36,46-48",
"    </a>",
"    ]. In many cases these arrhythmias are benign (eg, sinus tachycardia, nonsustained ventricular tachycardia [VT]), but in other cases the arrhythmias can be clinically",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodynamically significant (eg, ventricular fibrillation [VF], sustained VT).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular arrhythmias &ndash; Runs of nonsustained ventricular tachycardia (VT) are seen in up to five percent of patients, and can occur in patients with or without structural heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/36\">",
"       36",
"      </a>",
"      ]. On the other hand, a sustained ventricular arrhythmia generally occurs only in patients with clinically documented VT or long-lasting VF [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/13,36\">",
"       13,36",
"      </a>",
"      ]. Cardioversion can also induce VF, usually but not always after the administration of an asynchronous shock [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/13\">",
"       13",
"      </a>",
"      ]. The occurrence of ventricular arrhythmias does not appear to be related to the number of shocks and cannot be prevented by antiarrhythmic therapy. Conversely, antiarrhythmic drugs may contribute to the development of new arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atrial arrhythmias &ndash; Atrial arrhythmias can also occur following cardioversion. Approximately 30 percent of patients have a supraventricular tachycardia, primarily sinus tachycardia. However, AV nodal reentrant tachycardia and atrial flutter have been observed following cardioversion attempts for chronic atrial fibrillation (AF) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bradyarrhythmias and conduction abnormalities &ndash; Over 25 percent of patients have a bradycardia immediately after cardioversion, as cardioversion increases vagal tone. Sinus bradycardia and heart block may result in escape ventricular arrhythmias. The incidence is increased in patients with a previous history of inferior wall myocardial infarction, those who need multiple shocks to terminate the arrhythmia, and in patients receiving a beta blocker [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A transient left bundle branch block is occasionally seen after cardioversion, but high-degree atrioventricular block is more common. In one study of 75 patients who underwent 112 shocks, sinus bradycardia occurred in 18 patients and high-degree AV block in 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/46\">",
"     46",
"    </a>",
"    ]. Temporary pacing was necessary in 10 patients. The likelihood of requiring either external or transvenous cardiac pacing immediately after a cardioversion is much lower in clinical practice than this study suggests. The incidence appears to be less than 1 percent. Patients receiving antiarrhythmic drugs are more prone to develop bradycardia and asystole and an external pacemaker should be readily available in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/13,46\">",
"     13,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=see_link\">",
"     \"Temporary cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560851\">",
"    <span class=\"h3\">",
"     Thromboembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion may be associated with pulmonary or systemic thromboembolization. Thromboembolization after the return of synchronous atrial contraction has classically been attributed to the dislodgement of left atrial thrombi present at the time of cardioversion. This complication is more likely to occur in patients with atrial fibrillation (AF) who have not been anticoagulated prior to cardioversion. Patients with a previous embolism do not have an increased risk of embolization if anticoagulation of adequate intensity and length are administered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/51\">",
"     51",
"    </a>",
"    ]. The estimated incidence of thromboembolism varies, but in a large nonrandomized series that included 437 patients, thromboembolism occurred in 5.3 percent of patients who were not anticoagulated compared to 0.8 percent of those who were receiving anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/52\">",
"     52",
"    </a>",
"    ]. For patients with AF of at least 48 hours duration, the current recommendation is to anticoagulate patients for several weeks prior to and following cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560858\">",
"    <span class=\"h3\">",
"     Myocardial necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial necrosis, particularly of the epicardium, may occur as a result of high-energy shocks and is manifested by relatively small rises in serum CK-MB and troponin levels. In contrast, substantial elevations of either CK-MB or troponin following electrical cardioversion suggest the presence of myocardial injury from causes unrelated to the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the cause is unknown, it has been suggested that myocardial necrosis may be due to the sustained depolarization of a critical mass of myocardial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/38\">",
"     38",
"    </a>",
"    ]. The risk of myocardial necrosis appears related to the amount of energy delivered with each shock rather than to the number of shocks, although many repeated shocks may lead to myocardial damage and scarring.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 30 patients who underwent cardioversion, an increase in serum CK-MB was seen in only two patients, despite substantial release of CK from skeletal muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/53\">",
"       53",
"      </a>",
"      ]. Furthermore, the small release of CK-MB in this report cannot be considered diagnostic for myocardial damage since the total CK from skeletal muscle includes about 1 percent CK-MB [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/54\">",
"       54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"       \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The desire for improved specificity in the diagnosis of myocardial injury has led to measurement of the serum troponin levels. Among 38 patients undergoing elective cardioversion, only three patients had minimal elevations of troponin I (0.8 to 1.5",
"      <span class=\"nowrap\">",
"       &micro;g/L),",
"      </span>",
"      suggesting subtle myocardial injury [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/42\">",
"       42",
"      </a>",
"      ]. Two other studies, however, reported no elevations in troponin T following cardioversion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/43,55\">",
"       43,55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560865\">",
"    <span class=\"h3\">",
"     Myocardial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Global left ventricular dysfunction due to myocardial stunning may be seen in patients with cardiac arrest who have undergone successful cardiopulmonary resuscitation. This is related in part to defibrillation, but is also a result of the arrhythmia itself and due to the absence of cardiac output and coronary blood flow during the period of arrest with resultant ischemia. Myocardial dysfunction due to stunning may reverse within the first 24 to 48 hours after cardiac arrest. Thus, baseline evaluation of left ventricular function in such patients should be delayed for at least 48 hours after resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In animals, the severity of postresuscitation myocardial dysfunction is related, in part, to the energy used for defibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/57\">",
"     57",
"    </a>",
"    ]. Further support for this observation comes from another animal study comparing biphasic and monophasic waveforms for reversion of ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/58\">",
"     58",
"    </a>",
"    ]. Although lower-energy biphasic waveforms were as effective as higher-energy monophasic waveforms for restoration of sinus rhythm, there was less myocardial dysfunction after defibrillation with the use of biphasic waveforms.",
"   </p>",
"   <p>",
"    The process of electrical cardioversion may transiently injure or \"stun\" the atria as well [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560872\">",
"    <span class=\"h3\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema is a rare complication of cardioversion which is probably due to transient left atrial standstill or left ventricular dysfunction. It is unrelated to the amount of energy used. Pulmonary edema may be more common in patients with AF associated with valvular heart disease or left ventricular dysfunction. In this setting, the return of atrial systole after cardioversion can result in a significant elevation in left atrial pressure and pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560879\">",
"    <span class=\"h3\">",
"     Transient hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient hypotension can occur for several hours after cardioversion. Most patients require no therapy; if necessary, the fall in blood pressure usually responds to fluid replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/62\">",
"     62",
"    </a>",
"    ]. Although the mechanism is not certain, the hypotension may be related to vasodilation or the use of sedation during the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2560886\">",
"    <span class=\"h3\">",
"     Cutaneous burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following cardioversion or defibrillation, skin burns occur in 20 to 25 percent of patients and are more likely with improper technique and placement of electrodes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/63\">",
"     63",
"    </a>",
"    ]. The risk of burns is less with the use of biphasic waveforms and the use of gel-based pads [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/64\">",
"     64",
"    </a>",
"    ]. The prophylactic use of steroid cream or topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    prior to cardioversion reduces the pain and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INTERNAL CARDIOVERSION/DEFIBRILLATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3424163\">",
"    <span class=\"h2\">",
"     Technique and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internal or intracardiac cardioversion is an effective technique for patients in whom external cardioversion has failed to restore sinus rhythm. However, the need for internal cardioversion has been greatly diminished due to the efficacy of biphasic waveform defibrillators and the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    in restoring sinus rhythm. In addition, given the invasive nature of the procedure, specialized training is required to perform internal cardioversion. An",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force on clinical competency has published recommendations for technical and cognitive skills needed to perform internal direct current cardioversion (",
"    <a class=\"graphic graphic_table graphicRef57223 graphicRef65048 \" href=\"UTD.htm?16/54/17260\">",
"     table 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Internal cardioversion can be performed in various ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Using a preexisting implantable cardioverter defibrillator (ICD) to deliver a clinician-directed shock.",
"     </li>",
"     <li>",
"      Using epicardial wires placed during surgery or internal paddles applied directly to the epicardium in a patient with a sternotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two defibrillation electrodes are placed in the right atrium and coronary sinus or in the right atrium and left pulmonary artery, respectively, and then intracardiac shocks are delivered by an external defibrillator.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Internal cardioversion appears more effective for the restoration of sinus rhythm in patients with atrial fibrillation (AF) who have failed conventional external cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. As an example, one prospective study evaluated internal cardioversion in 141 patients with AF who had either failed external cardioversion or had had AF induced during an electrophysiology study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/69\">",
"     69",
"    </a>",
"    ]. AF was successfully terminated in 92 percent of patients with paroxysmal AF (&le;7 days duration), 89 percent of patients with AF of intermediate duration (8 to 30 days), and 70 percent of patients with chronic AF (&gt;30 days duration). No ventricular arrhythmias were induced during 1779 R wave synchronized shocks.",
"   </p>",
"   <p>",
"    Another prospective cohort study compared external and internal cardioversion in 187 patients with a mean duration of AF of 10 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/73\">",
"     73",
"    </a>",
"    ]. Internal cardioversion was significantly more effective than external cardioversion in restoring sinus rhythm (93 versus 79 percent). In addition, internal cardioversion was successfully in restoring sinus rhythm in 88 percent of patients in whom external cardioversion had failed.",
"   </p>",
"   <p>",
"    As with external cardioversion, the likelihood of restoration of sinus rhythm with internal cardioversion decreases with the duration of atrial fibrillation and increasing left atrial size [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/69\">",
"     69",
"    </a>",
"    ]. The recurrence rate is similar after both types of cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Internal cardioversion complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although internal cardioversion is an effective approach for restoring sinus rhythms in patients with atrial fibrillation refractory to pharmacologic or external electrical cardioversion, one study reported that complications occurred in 19 percent of patients, including low cardiac output from ventricular stunning, pericardial effusion, and a brief period of ventricular asystole requiring ventricular pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/74\">",
"     74",
"    </a>",
"    ]. Another report of 25 patients found that 36 percent developed transient bradycardia, related to sinus and atrioventricular nodal depression, requiring temporary ventricular pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/50/11050/abstract/75\">",
"     75",
"    </a>",
"    ]. Shocks of up to 20 joules did not affect the function of permanent pacemakers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Implantable atrial defibrillators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implantable automatic atrial defibrillators are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H2161774#H2161774\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Atrial defibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Implantable cardioverter-defibrillators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implantable cardioverter-defibrillators (ICDs) are in widespread use in patients with a history of sustained ventricular tachycardia or ventricular fibrillation and also for primary prevention in selected patients. In patients with an ICD, internal cardioversion can be attempted by a cardiologist using the device programmer to deliver the shock. The advantage of using the ICD is that it avoids the risk of a skin irritation from an external shock and the small chance of damage to the ICD system from the shock. The disadvantage of using the ICD is that it consumes some of the battery in the device and does not always work for cardioversion of atrial arrhythmias. Indications for and efficacy of ICDs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"       \"Patient information: Heart failure and atrial fibrillation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=see_link\">",
"       \"Patient information: Cardioversion (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H289870\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrical cardioversion and defibrillation have become routine procedures in the management of patients with cardiac arrhythmias. Cardioversion is the delivery of energy that is synchronized to the QRS complex, while defibrillation is nonsynchronized delivery of a shock randomly during the cardiac cycle. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrical cardioversion success rates approach 100 percent in patients with atrial flutter or atrial fibrillation of short duration and no structural heart disease, while the success rates are much lower in patients with chronic atrial fibrillation and concomitant mitral valve disease. (See",
"      <a class=\"local\" href=\"#H1682749\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Atrial fibrillation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Atrial flutter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrical cardioversion is usually successful in the acute treatment of ventricular tachycardia. If a distinct QRS and T wave are identified, synchronized cardioversion can be attempted. In contrast, synchronized cardioversion may be impossible or hazardous if distinct QRS complexes are not identified. As such, under these circumstances, nonsynchronized defibrillation should be used. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Ventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Defibrillation is the only definitive treatment for ventricular fibrillation (VF), with high success rates when performed promptly. However, the success rate falls substantially as the duration of ventricular fibrillation increases, probably due to myocardial ischemia, acidosis, and other metabolic changes. For these reasons, defibrillation as soon as possible has been considered to be the standard of care for VF (",
"      <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"UTD.htm?42/63/44022\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Ventricular fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once an arrhythmia has been identified, the most important factor in the likelihood of a successful cardioversion or defibrillation is the choice of the initial energy level to be delivered to the patient. The following are suggested initial energy requirements for monophasic and biphasic waveforms (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link&amp;anchor=H18#H18\">",
"       \"Basic principles and technique of cardioversion and defibrillation\", section on 'Energy selection for defibrillation'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For atrial fibrillation, 120 to 200 joules for biphasic devices and 200 joules for monophasic devices.",
"     </li>",
"     <li>",
"      For atrial flutter, 50 to 100 joules for biphasic devices and 100 joules for monophasic devices.",
"     </li>",
"     <li>",
"      For ventricular tachycardia with a pulse, 100 joules for biphasic devices and 200 joules for monophasic devices.",
"     </li>",
"     <li>",
"      For ventricular fibrillation or pulseless ventricular tachycardia, 120 to 200 joules for biphasic devices and 360 joules for monophasic devices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While electrical cardioversion and defibrillation are generally well tolerated, complications may occur. Most complications are self-limited (eg, changes in the electrocardiogram, hypotension related to sedation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vasodilation) or relatively benign (eg, skin irritation). However, providers should be aware of potential life-threatening complications such as post-cardioversion arrhythmias and thromboembolism. (See",
"      <a class=\"local\" href=\"#H2560757\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Internal or intracardiac cardioversion is an effective technique for patients in whom external cardioversion has failed to restore sinus rhythm. The need for internal cardioversion has been greatly diminished due to the efficacy of biphasic waveform defibrillators in restoring sinus rhythm. Given the invasive nature of the procedure, specialized training is required to perform internal cardioversion. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Internal cardioversion/defibrillation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2009115249\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. Philip Podrid, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/1\">",
"      Dahl CF, Ewy GA, Warner ED, Thomas ED. Myocardial necrosis from direct current countershock. Effect of paddle electrode size and time interval between discharges. Circulation 1974; 50:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/2\">",
"      Warner ED, Dahl C, Ewy GA. Myocardial injury from transthoracic defibrillator countershock. Arch Pathol 1975; 99:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/3\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/4\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/5\">",
"      Link MS, Atkins DL, Passman RS, et al. Part 6: electrical therapies: automated external defibrillators, defibrillation, cardioversion, and pacing: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/6\">",
"      Saliba W, Juratli N, Chung MK, et al. Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation. J Am Coll Cardiol 1999; 34:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/7\">",
"      Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999; 340:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/8\">",
"      Sung RJ. Facilitating electrical cardioversion of persistant atrial fibrillation by antiarrhythmic drugs: update on clinical trial results. Card Electrophysiol Rev 2003; 7:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/9\">",
"      Babbs CF, Yim GK, Whistler SJ, et al. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Heart J 1979; 98:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/10\">",
"      Troup PJ, Chapman PD, Olinger GN, Kleinman LH. The implanted defibrillator: relation of defibrillating lead configuration and clinical variables to defibrillation threshold. J Am Coll Cardiol 1985; 6:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/11\">",
"      Tacker WA Jr, Niebauer MJ, Babbs CF, et al. The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med 1980; 8:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/12\">",
"      Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989; 63:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/13\">",
"      DeSilva RA, Graboys TB, Podrid PJ, Lown B. Cardioversion and defibrillation. Am Heart J 1980; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/14\">",
"      Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/15\">",
"      Gurevitz OT, Ammash NM, Malouf JF, et al. Comparative efficacy of monophasic and biphasic waveforms for transthoracic cardioversion of atrial fibrillation and atrial flutter. Am Heart J 2005; 149:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/16\">",
"      Page RL, Kerber RE, Russell JK, et al. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 2002; 39:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/17\">",
"      Khaykin Y, Newman D, Kowalewski M, et al. Biphasic versus monophasic cardioversion in shock-resistant atrial fibrillation:. J Cardiovasc Electrophysiol 2003; 14:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/18\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/19\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/20\">",
"      Niebauer MJ, Brewer JE, Chung MK, Tchou PJ. Comparison of the rectilinear biphasic waveform with the monophasic damped sine waveform for external cardioversion of atrial fibrillation and flutter. Am J Cardiol 2004; 93:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/21\">",
"      Gallagher MM, Guo XH, Poloniecki JD, et al. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 2001; 38:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/22\">",
"      Mortensen K, Risius T, Schwemer TF, et al. Biphasic versus monophasic shock for external cardioversion of atrial flutter: a prospective, randomized trial. Cardiology 2008; 111:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/23\">",
"      Faddy SC, Powell J, Craig JC. Biphasic and monophasic shocks for transthoracic defibrillation: a meta analysis of randomised controlled trials. Resuscitation 2003; 58:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/24\">",
"      Morrison LJ, Dorian P, Long J, et al. Out-of-hospital cardiac arrest rectilinear biphasic to monophasic damped sine defibrillation waveforms with advanced life support intervention trial (ORBIT). Resuscitation 2005; 66:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/25\">",
"      Martens PR, Russell JK, Wolcke B, et al. Optimal Response to Cardiac Arrest study: defibrillation waveform effects. Resuscitation 2001; 49:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/26\">",
"      Stothert JC, Hatcher TS, Gupton CL, et al. Rectilinear biphasic waveform defibrillation of out-of-hospital cardiac arrest. Prehosp Emerg Care 2004; 8:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/27\">",
"      Tovar OH, Jones JL. Electrophysiological deterioration during long-duration ventricular fibrillation. Circulation 2000; 102:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/28\">",
"      Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA 1999; 281:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/29\">",
"      Wik L, Hansen TB, Fylling F, et al. Delaying defibrillation to give basic cardiopulmonary resuscitation to patients with out-of-hospital ventricular fibrillation: a randomized trial. JAMA 2003; 289:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/30\">",
"      VOGEL JH, PRYOR R, BLOUNT SG Jr. DIRECT-CURRENT DEFIBRILLATION DURING PREGNANCY. JAMA 1965; 193:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/31\">",
"      Schroeder JS, Harrison DC. Repeated cardioversion during pregnancy. Treatment of refractory paroxysmal atrial tachycardia during 3 successive pregnancies. Am J Cardiol 1971; 27:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/32\">",
"      Waller C, Callies F, Langenfeld H. Adverse effects of direct current cardioversion on cardiac pacemakers and electrodes Is external cardioversion contraindicated in patients with permanent pacing systems? Europace 2004; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/33\">",
"      Gould L, Patel S, Gomes GI, Chokshi AB. Pacemaker failure following external defibrillation. Pacing Clin Electrophysiol 1981; 4:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/34\">",
"      Levine PA, Barold SS, Fletcher RD, Talbot P. Adverse acute and chronic effects of electrical defibrillation and cardioversion on implanted unipolar cardiac pacing systems. J Am Coll Cardiol 1983; 1:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/35\">",
"      Manegold JC, Israel CW, Ehrlich JR, et al. External cardioversion of atrial fibrillation in patients with implanted pacemaker or cardioverter-defibrillator systems: a randomized comparison of monophasic and biphasic shock energy application. Eur Heart J 2007; 28:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/36\">",
"      Eysmann SB, Marchlinski FE, Buxton AE, Josephson ME. Electrocardiographic changes after cardioversion of ventricular arrhythmias. Circulation 1986; 73:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/37\">",
"      Van Gelder IC, Crijns HJ, Van der Laarse A, et al. Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter. Am Heart J 1991; 121:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/38\">",
"      Chun PK, Davia JE, Donohue DJ. ST-segment elevation with elective DC cardioversion. Circulation 1981; 63:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/39\">",
"      Zelinger AB, Falk RH, Hood WB Jr. Electrical-induced sustained myocardial depolarization as a possible cause for transient ST elevation post-DC elective cardioversion. Am Heart J 1982; 103:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/40\">",
"      Kok LC, Mitchell MA, Haines DE, et al. Transient ST elevation after transthoracic cardioversion in patients with hemodynamically unstable ventricular tachyarrhythmia. Am J Cardiol 2000; 85:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/41\">",
"      Reiffel JA, Gambino SR, McCarthy DM, Leahey EB Jr. Direct current cardioversion. Effect on creatine kinase, lactic dehydrogenase and myocardial isoenzymes. JAMA 1978; 239:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/42\">",
"      Allan JJ, Feld RD, Russell AA, et al. Cardiac troponin I levels are normal or minimally elevated after transthoracic cardioversion. J Am Coll Cardiol 1997; 30:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/43\">",
"      Neumayr G, Hagn C, G&auml;nzer H, et al. Plasma levels of troponin T after electrical cardioversion of atrial fibrillation and flutter. Am J Cardiol 1997; 80:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/44\">",
"      Reddy RK, Gleva MJ, Gliner BE, et al. Biphasic transthoracic defibrillation causes fewer ECG ST-segment changes after shock. Ann Emerg Med 1997; 30:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/45\">",
"      Ambler JJ, Deakin CD. A randomized controlled trial of efficacy and ST change following use of the Welch-Allyn MRL PIC biphasic waveform versus damped sine monophasic waveform for external DC cardioversion. Resuscitation 2006; 71:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/46\">",
"      Waldecker B, Brugada P, Zehender M, et al. Dysrhythmias after direct-current cardioversion. Am J Cardiol 1986; 57:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/47\">",
"      LEMBERG L, CASTELLANOS A Jr, SWENSON J, GOSSELIN A. ARRHYTHMIAS RELATED TO CARDIOVERSION. Circulation 1964; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/48\">",
"      PELESKA B. CARDIAC ARRHYTHMIAS FOLLOWING CONDENSER DISCHARGES AND THEIR DEPENDENCE UPON STRENGTH OF CURRENT AND PHASE OF CARDIAC CYCLE. Circ Res 1963; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/49\">",
"      Cohen TJ, Scheinman MM, Pullen BT, et al. Emergency intracardiac defibrillation for refractory ventricular fibrillation during routine electrophysiologic study. J Am Coll Cardiol 1991; 18:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/50\">",
"      Mehta PM, Reddy BR, Lesser J, Carson PE. Severe bradycardia following electrical cardioversion for atrial tachyarrhythmias in patients with acute myocardial infarction. Chest 1990; 97:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/51\">",
"      Elhendy A, Gentile F, Khandheria BK, et al. Safety of electrical cardioversion in patients with previous embolic events. Mayo Clin Proc 2001; 76:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/52\">",
"      Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969; 23:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/53\">",
"      Ehsani A, Ewy GA, Sobel BE. Effects of electrical countershock on serum creatine phosphokinase (CPK) isoenzyme activity. Am J Cardiol 1976; 37:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/54\">",
"      Lindberg K, Lundin A, Nordlander R, et al. Detection of acute myocardial infarction by a new, sensitive and rapid method for determination of creatine kinase B-subunit activity. Eur Heart J 1980; 1:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/55\">",
"      Goktekin O, Melek M, Gorenek B, et al. Cardiac troponin T and cardiac enzymes after external transthoracic cardioversion of ventricular arrhythmias in patients with coronary artery disease. Chest 2002; 122:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/56\">",
"      Kern KB, Hilwig RW, Rhee KH, Berg RA. Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning. J Am Coll Cardiol 1996; 28:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/57\">",
"      Xie J, Weil MH, Sun S, et al. High-energy defibrillation increases the severity of postresuscitation myocardial dysfunction. Circulation 1997; 96:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/58\">",
"      Sun S, Klouche K, Tang W, Weil MH. The effects of biphasic and conventional monophasic defibrillation on postresuscitation myocardial function. J Am Coll Cardiol 2001; 37:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/59\">",
"      Grimm RA, Stewart WJ, Maloney JD, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol 1993; 22:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/60\">",
"      Omran H, Jung W, Rabahieh R, et al. Left atrial chamber and appendage function after internal atrial defibrillation: a prospective and serial transesophageal echocardiographic study. J Am Coll Cardiol 1997; 29:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/61\">",
"      Gowda RM, Misra D, Khan IA, Schweitzer P. Acute pulmonary edema after cardioversion of cardiac arrhythmias. Int J Cardiol 2003; 92:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/62\">",
"      Resnekov L. High-energy electrical current and myocardial damage. Med Instrum 1978; 12:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/63\">",
"      Ambler JJ, Sado DM, Zideman DA, Deakin CD. The incidence and severity of cutaneous burns following external DC cardioversion. Resuscitation 2004; 61:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/64\">",
"      Ambler JJ, Deakin CD. A randomised controlled trial of the effect of biphasic or monophasic waveform on the incidence and severity of cutaneous burns following external direct current cardioversion. Resuscitation 2006; 71:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/65\">",
"      Ambler JJ, Zideman DA, Deakin CD. The effect of prophylactic topical steroid cream on the incidence and severity of cutaneous burns following external DC cardioversion. Resuscitation 2005; 65:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/66\">",
"      Ambler JJ, Zideman DA, Deakin CD. The effect of topical non-steroidal anti-inflammatory cream on the incidence and severity of cutaneous burns following external DC cardioversion. Resuscitation 2005; 65:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/67\">",
"      Tracy CM, Akhtar M, DiMarco JP, et al. American College of Cardiology/American Heart Association Clinical Competence Statement on invasive electrophysiology studies, catheter ablation, and cardioversion: A report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of Internal Medicine Task Force on Clinical Competence. Circulation 2000; 102:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/68\">",
"      Liebold A, Wahba A, Birnbaum DE. Low-energy cardioversion with epicardial wire electrodes: new treatment of atrial fibrillation after open heart surgery. Circulation 1998; 98:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/69\">",
"      L&eacute;vy S, Ricard P, Lau CP, et al. Multicenter low energy transvenous atrial defibrillation (XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol 1997; 29:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/70\">",
"      L&eacute;vy S, Lauribe P, Dolla E, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992; 86:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/71\">",
"      L&eacute;vy S. Internal defibrillation: where we have been and where we should be going? J Interv Card Electrophysiol 2005; 13 Suppl 1:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/72\">",
"      Schmitt C, Alt E, Plewan A, et al. Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol 1996; 28:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/73\">",
"      Alt E, Ammer R, Schmitt C, et al. A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion. Eur Heart J 1997; 18:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/74\">",
"      Mansourati J, Larlet JM, Salaun G, et al. Safety of high energy internal cardioversion for atrial fibrillation. Pacing Clin Electrophysiol 1997; 20:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/50/11050/abstract/75\">",
"      Prakash A, Saksena S, Mathew P, Krol RB. Internal atrial defibrillation: effect on sinus and atrioventricular nodal function and implanted cardiac pacemakers. Pacing Clin Electrophysiol 1997; 20:2434.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 983 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-5CD169F5DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11050=[""].join("\n");
var outline_f10_50_11050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H289870\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EXTERNAL CARDIOVERSION/DEFIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2562597\">",
"      Energy selection for defibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1682749\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Ventricular fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3424080\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cardioversion during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Cardioversion in patients with permanent pacemakers/ICDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2561692\">",
"      - Cardioversion in patients with digitalis toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2560757\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560837\">",
"      - ST segment and T wave changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560844\">",
"      - Arrhythmia and conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560851\">",
"      - Thromboembolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560858\">",
"      - Myocardial necrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560865\">",
"      - Myocardial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560872\">",
"      - Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560879\">",
"      - Transient hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2560886\">",
"      - Cutaneous burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INTERNAL CARDIOVERSION/DEFIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3424163\">",
"      Technique and efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Internal cardioversion complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Implantable atrial defibrillators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Implantable cardioverter-defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H289870\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2009115249\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/983|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/21/20819\" title=\"algorithm 1\">",
"      Adult tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/63/44022\" title=\"algorithm 2\">",
"      Adult cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/983|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/36/24140\" title=\"figure 1\">",
"      Defibrillation waveforms in ICDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/10/27811\" title=\"figure 2\">",
"      Flutter circuit right atrium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/983|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/9/6299\" title=\"table 1\">",
"      Antiarrhythmics and energy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/34/14891\" title=\"table 2A\">",
"      ACC AHA skills internal CV I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/33/10779\" title=\"table 2B\">",
"      ACC AHA skills internal CV II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/983|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?32/7/32884\" title=\"waveform 1\">",
"      12 lead ECG atrial flutter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=related_link\">",
"      Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37511?source=related_link\">",
"      Embolic risk and the role of anticoagulation in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/10/24738?source=related_link\">",
"      Patient information: Cardioversion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18201?source=related_link\">",
"      Restoration of sinus rhythm in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_50_11051="SEER pan ca survival";
var content_f10_50_11051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    SEER pancreatic cancer median survival in months",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Carcinoma grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median survival in months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        5.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        42.5",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SEER: Survival, epidemiology and end results database.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Longnecker, DS, Karagas, MR, Tosteson, TD, Mott, LA. Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in Asians, Blacks and Whites in the United States. Pancreas 2000; 21:338.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11051=[""].join("\n");
var outline_f10_50_11051=null;
var title_f10_50_11052="STOP-Bang questionnaire";
var content_f10_50_11052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F87572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F87572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    STOP-Bang questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"80%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         S",
"        </strong>",
"        noring: Do you snore loudly (louder than talking or heard through closed doors)?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         T",
"        </strong>",
"        ired: Do you often feel tired, fatigued, or sleepy during day?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         O",
"        </strong>",
"        bserved: Has anyone observed you stop breathing during your sleep?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         P",
"        </strong>",
"        ressure: Do you have or are you being treated for high blood pressure?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         B",
"        </strong>",
"        MI: &gt;35 kg/m2?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         A",
"        </strong>",
"        ge: &gt;50?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         N",
"        </strong>",
"        eck circumference: &gt;40 cm?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         G",
"        </strong>",
"        ender: Male?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    \"High risk\" for OSA: &ge;3 questions \"yes\".",
"    <br/>",
"    \"Low risk\" for OSA: &lt;3 questions \"yes\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology 2008; 108:812. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11052=[""].join("\n");
var outline_f10_50_11052=null;
var title_f10_50_11053="Causes strabismus";
var content_f10_50_11053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of strabismus in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Congenital",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pseudostrabismus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Prenatal drug exposure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Duane syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mobius syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Brown syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Congenital familial external ophthalmoplegia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Congenital third nerve palsy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Congenital fourth nerve palsy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Central nervous system insults",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Acquired",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Accommodative strabismus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intermittent exotropia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Interference with foveal vision (eg, cataracts)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Tumors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Increase intracranial pressure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Orbital injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Head trauma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Vascular disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Cerebral hemorrhage",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Ophthalmoplegic migraine",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Acquired (continued)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Neuromuscular disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Botulism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Myasthenia gravis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Benign sixth nerve palsy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Guillain-Barre syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Ocular myopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Multiple sclerosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Infections",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Encephalitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Meningitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Orbital cellulitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Gradenigo's syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Measles",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Diphtheria",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Polio",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Drugs and toxins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Lead",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Heavy metals",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Miscellaneous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Orbital myositis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Thyrotoxicosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Diabetes mellitus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hypoglycemia",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Strabismus. In: Signs and Symptoms in Pediatrics, 3rd ed, Tunnessen, WW Jr (Ed), Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p. 248.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_50_11053=[""].join("\n");
var outline_f10_50_11053=null;
var title_f10_50_11054="Contents: Global health";
var content_f10_50_11054=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Global health",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Global health",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Arboviruses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/13/15576\">",
"           Chikungunya fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/34/18985\">",
"           Clinical presentation and diagnosis of dengue virus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/55/4984\">",
"           Epidemiology of dengue virus infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/5/5208\">",
"           Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/5/36953\">",
"           Pathogenesis of dengue virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/50/808\">",
"           Prevention and treatment of dengue virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41095\">",
"           Ross River virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/21/15705\">",
"           Yellow fever",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemorrhagic viral infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/37/1624\">",
"           Diagnosis and treatment of Ebola and Marburg hemorrhagic fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/16/19721\">",
"           Epidemiology, pathogenesis, and clinical manifestations of Ebola and Marburg hemorrhagic fever",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/34/10794\">",
"           Adverse effects of antiretroviral therapy in developing countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/23/29050\">",
"           Prevention of HIV transmission during breastfeeding in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/2/21546\">",
"           The global human immunodeficiency virus pandemic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39018\">",
"           The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Measles",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/11/43192\">",
"           Clinical presentation and diagnosis of measles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/16/42246\">",
"           Epidemiology and transmission of measles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22793\">",
"           Prevention and treatment of measles",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Noma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/61/7129\">",
"           Noma (cancrum oris)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/31/5625\">",
"           Approach to the child with acute diarrhea in developing countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15928\">",
"           Diagnosis and treatment of Penicillium marneffei infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/33/33302\">",
"           Epidemiology and clinical manifestations of Penicillium marneffei infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/13/8409\">",
"           Epidemiology, diagnosis, and management of trachoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17753\">",
"           Severe acute respiratory syndrome (SARS)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-EB72A5EB8F-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_50_11054=[""].join("\n");
var outline_f10_50_11054=null;
var title_f10_50_11055="Contents: Pediatric signs and symptoms";
var content_f10_50_11055=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?10/42/10926\">",
"       Adult and Pediatric Emergency Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric signs and symptoms",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric signs and symptoms",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute and emergent",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/34/31272\">",
"           Apparent life-threatening event in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/36/16970\">",
"           Approach to acute vision loss in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17241\">",
"           Approach to hypertensive emergencies and urgencies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42057\">",
"           Approach to the child with a limp",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32472\">",
"           Approach to the child with acute ataxia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35977\">",
"           Approach to the child with headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22474\">",
"           Approach to the child with occult toxic exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/34/22056\">",
"           Approach to the child with palpitations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/38/9832\">",
"           Approach to the child with tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24521\">",
"           Approach to the infant or child with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17018\">",
"           Approach to the septic-appearing infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1033\">",
"           Approach to upper gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11593\">",
"           Causes of acute abdominal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/12/39113\">",
"           Causes of acute respiratory compromise in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/10/36007\">",
"           Causes of syncope in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7367\">",
"           Classification of trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29513\">",
"           Diagnostic approach to lower gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/35/4666\">",
"           Emergency department evaluation of acute onset psychosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/61/7130\">",
"           Emergent evaluation of acute respiratory compromise in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10201\">",
"           Emergent evaluation of acute upper airway obstruction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/52/14153\">",
"           Emergent evaluation of headache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11432\">",
"           Emergent evaluation of syncope in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/61/22490\">",
"           Emergent evaluation of the child with acute abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/16/27912\">",
"           Epidemiology and etiology of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31385\">",
"           Etiology and evaluation of cyanosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/54/24425\">",
"           Etiology and evaluation of the child with muscle weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/39/40569\">",
"           Evaluation of dysphagia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/47/13050\">",
"           Evaluation of earache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18086\">",
"           Evaluation of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/42/22185\">",
"           Evaluation of inguinal swelling in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/25/18842\">",
"           Evaluation of neck stiffness in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26841\">",
"           Evaluation of purpura in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/40/12936\">",
"           Evaluation of the immobile arm in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/10/15529\">",
"           Evaluation of vaginal bleeding in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/39/30329\">",
"           Evaluation of weight loss in infants over six months of age, children, and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/33/23065\">",
"           Management of hypertensive emergencies and urgencies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33768\">",
"           Overview of blunt abdominal trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40457\">",
"           Traumatic causes of acute shoulder pain and injury in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ambulatory",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41417\">",
"           Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/34/12840\">",
"           Approach to the child with an enlarged spleen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43880\">",
"           Approach to the child with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33128\">",
"           Approach to the child with peripheral lymphadenopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34004\">",
"           Approach to the infant with hypotonia and weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/36/34376\">",
"           Approach to the pediatric patient with vision change",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30744\">",
"           Causes of peripheral lymphadenopathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/63/25591\">",
"           Causes of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/27/10680\">",
"           Clinical features and etiology of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24295\">",
"           Clinical manifestations and evaluation of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25975\">",
"           Definition and evaluation of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11160\">",
"           Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15177\">",
"           Evaluation and management of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7288\">",
"           Evaluation and management of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28074\">",
"           Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/697\">",
"           Evaluation of acute pelvic pain in the adolescent female",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/13/13529\">",
"           Evaluation of diarrhea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/24/29064\">",
"           Evaluation of dizziness in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/29/43479\">",
"           Evaluation of dysuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14937\">",
"           Evaluation of oligomenorrhea in adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/9/24728\">",
"           Evaluation of otorrhea (ear discharge) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/27/12729\">",
"           Evaluation of pallor in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/31/39415\">",
"           Evaluation of sore throat in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1306\">",
"           Evaluation of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4102\">",
"           Evaluation of the child with hoarseness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14057\">",
"           Evaluation of the child with joint pain or swelling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23706\">",
"           Overview of the causes of limp in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26072\">",
"           Vulvovaginal complaints in the prepubertal child",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-AF391AE3A8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_50_11055=[""].join("\n");
var outline_f10_50_11055=null;
